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ABSTRACT 
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Philosophy in Chemical Pathology at The Chinese University of Hong Kong in 
June 2009 
Hepatocellular carcinoma (HCC) is the fifth most common cancers in the world 
and is the third leading cause of cancer death (Parkin et al’ 2005). The diagnosis of 
HCC relies on the measurement of serum a-fetoprotein (AFP) level which has 
already been used for 40 years. The discovery of promoter hypermethylation of 
tumor suppressor genes (TSGs) in HCC tissues has opened up the possibility of 
using methylated TSGs as potential markers for HCC. 
Methylation-specific PCR (MSP) has been a commonly used technique for the 
detection of aberrant DNA methylation. However, the detection rates of 
methylated TSGs in blood using MSP were much lower that their detection in 
tumor tissues. This was likely resulted from the degradation of DNA during the 
bisulfite conversion step of MSP (Grunau et al, 2001). In this regard, Chan et al. 
developed a non-bisulfite-based approach to detect methylated RASSFIA in 
plasma (Chan et al, 2008a). This method is termed methylation-sensitive 
restriction enzymes-mediated real-time quantitative PCR (MSRE-qPCR). Using 
this method, hypermethylated RASSFIA sequences could be detected in the serum 
of 93% HCC patients (Chan et al, 2008a). As the sensitivity was remarkably 
enhanced by this approach, low concentrations of methylated RASSFIA sequences 
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were also detected in the serum of 58% hepatitis B virus (HBV) carriers. This 
observation was postulated to be due to the release of methylated sequences from 
the nonmalignant hepatitic liver as the hypermethylation of RASSFIA is an early 
event in HCC pathogenesis and could be observed in patients with nonmalignant 
conditions such as cirrhosis and chronic hepatitis (Chan et al’ 2008a). In this 
project, I have studied the detectability of other aberrantly methylated TSGs in the 
plasma of HCC patients to determine if the combination of these markers can 
provide a more accurate diagnostic test for HCC than using RASSFIA alone. 
Using MSRE-qPCR, promoter hypermethylation of GSTPl, SOCSl, APC andpl6 
genes was detected in the tumor tissues of 78.6%, 64.3%, 87.5% and 89.3% HCC 
patients (n=55), respectively. The detection rates for these aberrantly methylated 
sequences in the plasma samples of HCC patients were 42.9%, 35.7%, 32.1% and 
58.9%, respectively. In contrast, these sequences were respectively detected in 
3.6%, 3.6%, 0% and 9.1% of chronic hepatitis B carriers (n=56). Aberrantly 
methylated GSTPl, SOCSl and pl6 sequences were not detectable in any of the 
healthy control subjects (n=58) whereas methylated APC sequences were detected 
in 3.4% healthy subjects. Overall, 76.8%, 14.5% and 3.4% of HCC patients, HBV 
carriers and healthy subjects, respectively, had one or more aberrantly methylated 
tumor suppressor genes {GSTPl / SOCSl / APC / pl6) detected in plasma. In 
addition, 72.0% HCC patients with normal serum AFP concentration had at least 
one aberrantly methylated tumor suppressor gene detected in plasma. The 
combination of plasma methylation markers with AFP measurement increased the 
sensitivity of HCC detection from 55.4% to 87.5% while the specificity is 
decreased from 90.9% to 7 8 . 2 % . � 
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In conclusion, the detection of aberrantly methylated GSTPl, SOCSl, APC and 
pl6 genes in plasma using MSRE-qPCR is potentially useful for the detection of 
HCC. In contrast to RASSFJA, aberrantly methylated sequences of these four 
TSGs are infrequently detected in the plasma of chronic HBV carriers. These tests 
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SECTION I: BACKGROUND 
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Hepatocellular carcinoma 
Chapter 1: Hepatocellular Carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and is 
the third leading cause of cancer deaths (Parkin et al, 2005). The number of deaths 
associated with HCC remains high despite medical advances over the past few 
decades. HCC demonstrates a preferential geographic distribution in Sub-Saharan 
Africa and Asia where hepatitis B and C viral infections are prevalent (Bosch et al, 
2004; Llovet et al，2003). This fact has highlighted the importance of chronic viral 
infection as an etiology of HCC. 
One important reason for the high mortality for HCC is the late presentation of the 
HCC patients as early HCC is typically asymptomatic. Over the last few decades, 
efforts have been paid to develop better diagnostic tools for detecting early HCC, 
particularly in high risk groups. However, the existing tests have failed to provide 
desirable sensitivity and specificity for HCC surveillance purpose. 
This chapter will discuss the epidemiology, etiology and clinical presentation of 
HCC as well as the current diagnostic methods and treatment modalities for HCC 
patients, and also the past efforts in HCC marker development. 
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1.1. Epidemiology of HCC 
In 2007, there were 711,000 new liver cancer cases and about 680,000 people died 
from liver cancer globally (Global Cancer Facts and Figures, American Cancer 
Society, 2007). HCC consists of 70-80% of total cases of liver cancer and this thesis 
would focus on it. HCC is the third cancer killer in men and the sixth in women. The 
male:female ratio for HCC is 3:1. 
HCC demonstrates an unbalanced geographical distribution in which more than 80% 
of cases come from developing countries (Parkin et al, 2005). Areas with high HCC 
incidence in the past such as Hong Kong, Shanghai and Singapore, have shown a 
decrease in incidence while the HCC incidence in Central Europe and North America 
where HCC was rare in the past has increased. The reduction of HCC incidence in 
the former regions is thought to be attributed to the HBV vaccination programs and 
the better control of aflatoxin exposure in these areas. The increasing incidence in the 
latter regions may be due to the increasing prevalence of hepatitis C infection and the 
influx of immigrants from countries with high incidence (But et al, 2008; El-Serag et 
al, 2003). 
1.2. Etiology of HCC 
The pathogenesis of HCC is complex and involves the interactions of genetic 
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abnormalities, exposure to dietary and environmental hepatotoxins and infection with 
hepatotropic viruses. To date, the most established etiological factors for HCC 
include cirrhosis, HBV and HCV infections, and plant carcinogen aflatoxin B 
exposure. 
1.2.1. Cirrhosis 
About 80-90% of HCC patients were found to be associated with cirrhosis but 
cirrhosis does not always lead to HCC development (Llovet et al, 2003). 
Precancerous cirrhotic livers appear to have large nodules and thin intervening 
stroma which undergo vigorous regenerative activities and DNA synthesis. This cell 
regeneration process is an oncogenic event which promotes cell division, selection 
and clonal expansion of cells with malignant potential. Cirrhotic livers with 
adenomatosis hyperplastic nodules are considered as having high potential for HCC 
development (Borzio et al, 1995; Livraghi et al, 1997; Okuda, 1992). Three to five 
percent of cirrhotic patients would develop HCC each year (Sangiovanni et al, 2004; 
Tsukuma et al’ 1993). 
1.2.2. Hepatitis virus 
HBV infection is an important risk factor for HCC especially if one acquires the 
infection early in life. HBV is highly endemic in Asia and sub-Saharan Africa. In this 
area, a lot of people contract HBV infection during childhood when their immunity 
against HBV is weak. As a result, they become chronic carriers of HBV. The risk for 
HCC development in chronic HBV carriers greatly depends on the age of acquiring 
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the infection. The lifetime risk is about 40% if infected in childhood and 10% if 
infected in adulthood. Overall, 0.26% to 0.6% of chronic HBV carriers would 
develop HCC each year. The risk would increase to 1% and 2-3% in patients with 
active hepatitis and cirrhosis, respectively (Michielsen et al, 2005). HBV infection 
can predispose to HCC possibly through viral integration into the host genome of the 
liver cells and result in transactivation of proto-oncogenes, inactivation of tumor 
suppressor genes, and activation of growth factors. The HBV encoded HBx gene can 
also act on cyclin A, protein kinases and DNA repair system and lead to HCC 
development (Chan & Sung, 2006). 
Hepatitis C virus (HCV) infection is an important etiological factor for HCC in Japan 
and western countries. HCV-related HCC represents 70% of all cases in Japan 
(Umemura et al, 2009). In the U.S., 47% of HCC patients have been infected with 
HCV but only 15% of them have chronic HBV infection. HCV transmission is 
mainly through intravenous drug injection in drug abusers and transfusion of 
unscreened blood and blood products (El-Serag, 2004). The pathogenic mechanism 
involved in HCV-related HCC is likely to exhibit differences from that of 
HBV-associated HCC as HCV is a single-stranded RNA virus and is incapable of 
integrating into the genome of infected liver cell. HCV-related HCC is caused by 
chronic inflammation, cell death, proliferation and cirrhosis (But et al, 2008). 
1.2.3. Plant carcinogens 
Aflatoxin intake is a risk factor for HCC in developing areas of the subtropical 
regions of the world where the hygiene conditions and weather favor the growth of 
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the fungus Aspergillus flavis. People consume grains, peanuts and food products 
contaminated by aflatoxins are prone to develop HCC (Smela et al, 2001). 
1.2.4. Miscellaneous factors 
Alcohol consumption may not have direct carcinogenic effect on the liver. However, 
excessive consumption of alcohol can led to cirrhosis and hence, increase the risk of 
HCC development (Morgan et al, 2004). Potential carcinogens have also been 
identified in pharmaceutical, cosmetic products, cleaning reagents, organic solvents 
and pesticides (Lau, 2008). 
1.3. Clinical presentation of HCC 
HCC is usually asymptomatic until the tumor grows to a substantial size and invades 
the neighboring tissues. When a large proportion of the parenchyma is replaced by 
tumor cells and the rest of the liver reserves cannot sustain its functions, the clinical 
symptoms related to functional disturbances would start to appear (Lau, 2008). The 
symptoms of HCC are highly variable and include jaundice, ascites, palpable mass in 
the abdomen, pain, fever, variceal bleeding, anorexia, confusion and other 
constitutional syndrome (Livraghi et al, 1997). In patients presenting with symptoms 
of cirrhosis, they may die from liver failure instead of tumor invasion. 
1.4. Existing diagnostic tests for HCC 
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1.4.1. Alpha-fetopwtein (AFP) 
Serum alpha-fetoprotein (AFP) is the most commonly used tumor marker for HCC 
although it was first discovered forty years ago. AFP is a serum protein synthesized 
physiologically by fetal livers and its level would decline gradually after birth. 
However, AFP would also be secreted abnormally by HCC cells. A serum 
concentration of 20 |xg/L is commonly used as a cut-off value to differentiate HCC 
patients from normal individuals. The diagnostic sensitivity of AFP for HCC is 
40-60% and the specificity is 80-90% (Farinati et al, 2006; Wright et al, 2007). In 
addition, chronic hepatitis and cirrhotic patients may also have elevated AFP levels 
and this fact may limit the application of AFP measurement for detecting HCC in this 
group of patients (Zhou et al, 2006). In this regard, a search of better markers that are 
more sensitive and specific for HCC is an ongoing effort by workers in the field 
(Marrero & Lok，2004). 
1.4.2. Imaging 
Ultrasound is a common imaging modality that is used complementarily with AFP 
measurement for the screening of HCC. It is relatively inexpensive, safe and easy to 
perform. However, it is operator-dependent and labor-intensive. As a large proportion 
of HCC patients have cirrhotic livers, accurate differentiation between small HCC 
and benign liver lesions may be difficult (Rapaccini et al, 2004). Computer-assisted 
tomography is also a commonly utilized imaging technique for HCC detection. It is 
particularly useful for measuring the size of the tumor, detecting metastasis and 
identifying vascular invasion. 
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1.5. Treatment of HCC 
Tumor resection and liver transplantation are the two common treatment modalities 
that can be used with curative intent. Palliative treatments like tumor ablation or 
embolization are also offered to patients that are not curable with surgery for 
symptomatic relief. 
1.5.1. Surgical Resection and Transplantation 
The median 5-year survival rates for patients who have undergone surgical resection 
and transplantation are approximately 50% and 70%, respectively (Llovet et al, 
1999). However, less than one third of HCC patients are suitable for surgical 
resection of the tumor as most patients present with either locally advanced diseases 
or distant metastases. Moreover, many HCC patients have cirrhosis and the 
regenerating capacity of the hepatocytes is greatly compromised. In such patients, as 
the portion of resectable liver is limited and the residual liver tissue may be prone to 
exhibit tumor recurrence. In this regard, liver transplantation may be used for 
patients with cirrhosis and poor liver function reserves. However, the limiting factor 
for liver transplantation is always the difficulty in having organ donation 
opportunities. 
1.5.2. Tumor Ablation or Embolization 
For patients not suitable for curative-intent tumor resection, tumor ablation or 
一 g 
Hepatocellular carcinoma 
embolization methods can be used as palliative treatments. Ablation refers to local 
methods of tumor destruction and includes radiofrequency ablation, cryosurgery and 
ethanol injection. Radiofrequency ablation uses a needle-like probe to release high 
frequency alternating current and produces frictional heating to destroy tumor cells. 
Cryosurgery uses a very cold metal probe to freeze and destroy tumor cells. Ethanol 
injection destroys the tumor by injecting concentrated alcohol directly into the tumor 
to kill cancer cells. 
Embolization involves the blockage of a blood-supplying artery to the tumor by 
surgical or chemical means (chemoembolization). The principle is to delay the 
invasion and progression of the cancer by depriving the tumor of nutrient supplies. 
However, embolization of arteries also reduces blood supply for normal liver tissues. 
Studies in the Caucasians and Japanese showed that chemoembolization is effective 
and results in 5-year survival rates higher than 50% in patients who have received 
this treatment (Llovet & Bmix，2003). 
1.5.3, Chemotherapy and Radiotherapy 
Doxorubicin is the most effective chemotherapeutic agent that shrinks the size of the 
tumor. Doxorubicin is a topoisomerase II inhibitor and it suppresses tumor growth by 
inhibiting DNA synthesis and interfering with DNA strand separation and helicase 
activity (Gewirtz, 1999). The drug can be administered intravenously or orally. 
However, chemotherapeutic drugs often produce side effects as it also kills some 
normal cells. Side effects include nausea, vomiting, loss of appetite, loss of hair, and 
mouth sores. More severe side effects also include susceptibility to infection, 
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bleeding tendency and anemia because of bone marrow suppression. 
Radiation therapy can shrink the tumor and alleviate symptoms like pain although it 
does not improve survival of HCC. With advanced imaging techniques, radiation can 
target tumor cells more precisely and reduce the damage to normal liver cells. 
1.6. Tumor marker development for HCC detection 
The mortality and morbidity rates of HCC remain high despite advances in 
diagnostics and treatments. This is mainly because HCC patients are often diagnosed 
with advanced disease. Furthermore, a large proportion of these patietns have poor 
liver reserves due to co-existing chronic hepatitis and cirrhosis. Early detection of 
HCC is crucial to survival because patients with locally advanced disease or distant 
metastasis are not suitable for curative-intent surgical treatment. However, current 
diagnostic method of measuring serum AFP concentration offers low sensitivity and 
specificity for HCC. Thus, only less than 60% of HCC patients have elevated AFP 
levels whereas patients with flare up of chronic hepatitis would also have increased 
AFP levels. Though imaging is added to the diagnostic regimen to improve the 
detection accuracy of AFP, it is still a challenge to detect small tumors with size 




Table 1.6.1. Different types of HCC tumor markers 
Categories Examples 
Oncofetal antigens and a-fetoprotein, a-fetoprotein-L3, 
glycoprotein antigens monosialylated a-fetoprotein and glypican-3 
Enzymes and a-L-fucosidase, des-gamma-carboxy 
Isoenzymes prothrombin and Golgi protein 73 
transforming growth factor-pi and 
Growth factors . . . 
insulin-like growth factor-II 
a-fetoprotein mRNA, telomerase reverse 
Genes transcriptase mRNA and hypermethylated 
tumor suppressor genes 
(Modified from Zhou et al , 2006) 
1.6.1. Oncofetal antigens and glycoprotein antigens 
a-fetoprotein-L3 (AFP-L3) is one glycoform of the a-fetoprotein family named after 
its binding capability to the lectin Lens culinaris agglutin (LCA). AFL-L3 is the 
major glycoform present in the serum of HCC patients. It can be detected in about 
35% of patients with small HCC (<3 cm) (Oka et al, 2001). Another study in 
monosialylated a-fetoprotein showed a sensitivity of 61% and a specificity of 80% in 
patients with moderately elevated serum AFP levels (Poon et al, 2002). Glypican-3 
(GPC-3) is a cell-surface glycoprotein and present in a significantly higher 
percentage in HCC patients than in controls and cirrhosis patients. Glypican-3 can be 
detected in the serum of 53% HCC patients using enzyme-linked immunosorbent 
assay (ELISA) (Capurro et al, 2003). 
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1.6.2. Enzymes and isoenzymes 
a-L-fucosidase (AFU) is a ubiquitously expressed lysosomal enzyme that hydrolyzes 
fucose glycosidic linkages of glycoprotein and glycolipids. Its activity is moderately 
elevated in HCC patients compared to patients with cirrhosis and normal individuals. 
It is not very useful alone but together with AFP measurement, the sensitivity can be 
up to 82.6% (Tangkijvanich et al, 1999). Des-gamma-carboxy prothrombin (DCP) is 
a protein induced by vitamin K deficiency and an abnormal product from liver 
carboxylation disturbance during the formation of thrombogen (Suzuki et al, 2005). 
It can differentiate HCC from nonmalignant hepatopathy and the sensitivity is 57% 
using DCP alone (Ikoma et al, 2002). Golgi protein 73 (GP 73) is a protein with 
upregulated expression in heptocytes of patients with hepatitis and cirrhosis. It had a 
sensitivity of 69% and a specificity of 86% with an area under the receiver operating 
characteristic curve of 0.79 (Marrero et al, 2005). 
1.6.3. Growth factors 
Transforming growth factor-pi (TGF-pl) is a multifunctional cytokine involved in 
the regulation of growth and differentiation in both normal and transformed cells. 
The sensitivity for HCC of this marker is 68.4% using a cutoff level of 800 pg/mL. 
However, an elevated TGF-pi level can also be observed in cirrhotic patients (Song 
et al, 2002)• Insulin-like growth factor-II (IGF-II) is a tumor-specific growth factor 
released into the peripheral blood by tumor cells. The sensitivity of IGF-II is only 
42% and it is correlated to AFP levels and thus lowers the diagnostic potential of this 
marker (Tsai et al, 2003). 
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1.6.4. Genetics and epigenetics - rtiRNA and methylation 
a-fetoprotein mRNA (AFP mRNA) is found to be originated from escaped tumor 
cells into the circulation and correlated with high mortality rates after surgical 
resection. A study showed that serum AFP-mRNA quantification together with AFP 
can predict clinical metastasis or recurrence in 56% of patients during a 4-year 
follow-up (Wong et al, 2001). Another study of human telomerase reverse 
transcriptase (hTERT) mRNA by reverse-transcription-PCR reported a sensitivity 
and specificity of 88% and 70%, respectively. The diagnostic accuracy is proved to 
be superior to AFP mRNA, AFP and des-gamma-carboxy prothrombin in HCC 
diagnosis (Miura et al, 2005). 
In 1999, methyated pl6 sequences were shown to be detectable in the plasma of 
HCC patients (Wong et al, 1999). Using methylation-sensitive PCR (MSP), promoter 
hypermethylation of the pl6 gene was observed in 73% of HCC tissues. Among the 
HCC patients with hypermethylation of pl6 in the tumor tissues, methylated pl6 
sequences were detected in 81% of their plasma. Promoter hypermethylation of pl6 
is associated with the silencing of gene expression and is an early event in 
carcinogenesis. The detection of aberrantly methylated TSGs in plasma represents a 
new approach for cancer detection (Hoque et al, 2006). 
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Chapter 2: Hypermethylation of tumor suppressor genes in 
cancer 
2.1. Cancer epigenetics 
It has long been regarded that cancer is a genetic disease characterized by germline 
or somatic mutations. However, since the aberration of gene methylation in cancer 
was discovered 25 years ago, a large body of evidences has been accumulated that 
suggests epigenetic changes also play an important role in cancer initiation, 
progression and metastasis. Epigenetics refers to a heritable change in gene 
expression pattern that do not involve alterations in the primary sequence of a gene 
(Herman & Baylin, 2003). It is shown that cancer progression involves a series of 
epigenetic events of which transcriptional silencing by promoter hypermethylation is 
considered to be an early one. Among many epigenetic phenomena, promoter 
hypermethylation in tumor suppressor genes has been most extensively studied. 
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Figure 2.1.1. Pathway for the methylation of cytosine in the mammalian genome 
Cytosine is converted to 5-methyl cytosine catalyzed by DNA methyltransferases 
(DNMTs) using S-adenosyl-methionine as the methyl donor (Modified from Herman 
and Baylin 2003). 
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2.2. DNA methylation in normal cells 
In mammals, DNA methylation is a covalent addition of methyl group to the 5' 
position of cytosine within a CpG dinucleotide using S-adenosyl-methionine as a 
methyl donor and catalyzed by DNA methyltransferases (DNMTs) (Herman & 
Baylin, 2003). Around 70% of CpG dinucleotides are methylated in the mammalian 
genome. The distribution of CpG dinucleotides is predominantly accumulated in 
small stretches of DNA of 0.5-4 kb known as CpG islands and they are typically 
positioned at the 5'end of genes where transcription begins (Bird, 1986). If the CpG 
sites in a promoter region involved in transcriptional regulation are methylated, the 
transcription will be blocked and this process is termed "transcriptional silencing". 
DNA methylation is a very complicated process which involves a number of 
mediators such as enzymes, DNA-binding proteins, transcription factors and histories. 
The detailed mechanism of methylation is still unclear but the key process of CpG 
methylation is believed to be mediated by a class of enzymes termed DNA 
methyltransferases (DNMTs), which consist of three known biologically active 
enzymes in mammalian cells, DNMTl, DNMT3a and DNMT3b. DNMTBa and 
DNMT3b initiate de novo methylation and establish new DNA-methylation patterns 
(Okano et al, 1999; Okano et al, 1998 ； Pradhan et al, 1999). DNMTl is expressed 
ubiquitously in somatic tissues and is preferentially active towards hemimethylated 
CpG sites after DNA replication (Pradhan et al, 1999). Studies also revealed that 
DNMTs may contribute to transcriptional repression in mechanisms other than 
methylation such as binding to other proteins like histone deacetylases (Herman & 
Baylin, 2003). Besides DNMTs, methyl-CpG-binding proteins (MBPs) also appear to 
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affect methylation-dependent gene silencing. These DNA binding proteins are 
specific to methylated CpG dinucleotide. To date, there are five known MBPs in 
mammals which are MeCP2, MBDl, MBD2, MBD4 and Kaiso (Tollefsbol, 2009). 
Some of the MBPs also link DNA methylation and chromatin remodeling-mediated 
gene silencing by associating with transcriptional repressors and recruiting histone 
deacetylases to methylated DNA in regions of transcriptional silencing (Jones & 
Baylin, 2002). 
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Figure 2.2.1. CpG-rich promoter in transcriptionally active and transcriptionally 
repressed state 
(adapted from Jones and Baylin, 2002) 
a. This is an unmethylated and transcriptionally permissive promoter with a CpG 
island. The nucleosomes with acetylated histories (ellipses shown in light green with 
red asterisk) are widely spaced and this type of chromatin allows the transcription 
activator complex to access, b. This is a hypermethylated and transcriptionally 
repressive promoter with compacted, highly deacetylated nucleosomes. This leads to 
transcriptional silencing. (CA, co-activator protein; HAT, histone acetyltransferase; 
HPl, chromodomain protein HP la; TF, transcription factor) 
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2.3. Physiological role of DNA methylation in normal cells 
DNA methylation usually correlates with a repressed gene expression and it can help 
maintain the noncoding DNA in an inert state. Hypermethylated DNA results in a 
late replication and consequently leads to the formation of inactive chromatin and 
facilitates transcriptional silencing. It is crucial to prevent the transcription of large 
parts of genome such as repetitive DNA, transposons or inserted viral sequences 
which might harm the cell (Herman & Baylin，2003). Besides the silencing of 
noncoding region in the genome, other important physiological processes like 
X-chromosome inactivation and genomic imprinting are also mediated by DNA 
methylation. 
X-chromosome inactivation occurs in most genes on the X chromosome. One of the 
two copies of these genes is silenced in females so as to compensate the increased X 
chromosome dosage in female cells compared with male cells (Reik & 
Ferguson-Smith, 2005). DNA methylation is one of the mechanisms for 
X-chromosome inactivation by which the selected silencing regions are 
transcriptionally repressed. One of the crucial events is the exclusive expression of 
noncoding X-(inactive)-specific transcript {XIST) RNA from the X chromosome to 
be inactivated, and hence initiates chromatin remodeling later to prevent transcription 
(Straub & Becker，2007). 
Genomic imprinting is defined as the epigenetic marking of parts of the genome of a 
diploid organism with respect to their parental origin that the imprinted genes are 
preferentially expressed from only one of the parental copies (Paulsen & 
— — 
Hypermethylation of tumor suppressor genes in cancer 
Ferguson-Smith, 2001). The DNA sequences responsible for establishing imprinting 
are named as imprinting control regions (ICRs). Differential patterns of DNA 
methylation in these regions may act as epigenetic marks to mediate the imprinting 
on neighbouring genes. Various ways have been found in different loci for 
monoallelic expression. One example is the Igf2/H19 locus. This pair of genes are 
reciprocally expressed under the control of shared enhancer elements. The 
differentially methylated domain (DMD) of Igfl is located upstream to the HI9 
promoter. On the paternal allele, the DMD acquires methylation during 
spermatogenesis and facilitates the enhancer to promote transcription and silence the 
expression of HI 9. In contrast, the hypomethylated maternal DMD is bounded by 
the methylation-sensitive boundary factor CTCF, which hinders the access of 
enhancer to Igf2 and allows the expression of HI 9 (Wood & Oakey, 2006). 
Imprinting errors in this region chromosome (llpl5.5) are associated with the 
development of the Beckwith-Wiedemann syndrome (Weksberg et al, 2005) and 
Wilms tumor (Algar et al, 2007). Another region involved in a genomic imprinting 
disorder is located on chromosome 15qll-ql3. Loss of paternal contribution in this 
locus results in the Prader-Willi syndrome while loss of maternal contribution leads 
to the development of Angelman syndrome (Glenn et al, 2000). 
2.4. Aberrant DNA methylation in cancer 
There are two major epigenetic disruptions in cancer. The first one is DNA 
hypomethylation of repetitive sequences, noncoding DNA, the inactive 
X-chromosome and imprinted regions; and the second one is DNA hypermethylation 
in the promoters of tumor suppressor genes. 
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2.4.1. DNA hypomethylation in cancer 
Global DNA hypomethylation is one of the earliest epigenetic alterations discovered 
in human cancers (Feinberg & Tycko，2004). During carcinogenesis, the degree of 
hypomethylation of genomic DNA is increased with the stage of the tumor 
progression. More frequent mitotic recombination by hypomethylation results in 
chromosomal rearrangements, deletions and translocations and thus would affect the 
stability of the chromosomes. In addition, those previously silenced regions such as 
long interspersed nuclear elements 1 and Alu sequences may be reactivated and leads 
to the expression of inserted viral genes or imprinted genes on the inactive 
X-chromosome (Esteller, 2008). Some oncogenes are shown to be activated such as 
the hypomethylation of Hpall sites in the 3’ region of H-Ras found in non-small cell 
lung cancer (Vachtenheim et al, 1994). As another example, promoter 
hypomethylation of the c-myc gene has also been found in several tumor cell lines 
(Cheah et al, 1984). 
2.4.2. DNA hypermethylation in cancer 
Promoter hypermethylation of tumor suppressor genes is regarded as an early event 
in the pathogenesis of cancers. DNA hypermethylation has resulted in the 
transcriptional repression of tumor suppressor genes and DNA repair systems. 
Knudson's two-hit hypothesis (Knudson, 2001) postulates that for the function of a 
tumor suppressor gene to be disrupted, it requires a complete loss of function of both 
copies of the involved gene. Aberrant promoter methylation is an important event 
that can be the first hit or the second hit in carcinogenesis. For a tumor suppressor 
gene, mutation in coding regions can occur in inherited cancer or sporadic cancer to 
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constitute the first hit while promoter hypermethylation can occur in somatic cancer 
to constitute the first hit. In an inherited cancer, chromosomal deletions involving the 
second copy or promoter hypermethylation can be the second hit in tumors while in 
somatic cancers, chromosomal deletions often constitutes the second hit to eliminate 
the remaining gene copy (Herman & Baylin, 2003). Promoter hypermethylation has 
been demonstrated in many tumor suppressor genes such as pl6 {cyclin-dependent 
kinase inhibitor 2A), VHL (gene associated with von Hippel-Lindau disease), APC 
{adenomatosis polyposis coli) and BRCAl {breast-cancer susceptibility gene 1) 
(Esteller et al, 2000a; Esteller et al, 2000b; Herman et al, 1994; Merlo et al, 1995). 
Compared with hypomethylation, hypermethylation is studied more extensively of its 
role and their diagnostic potential in different cancers. 
2.5. Development of methylation markers in tumor diagnosis 
The development of better tumor markers may be useful for reducing the mortality of 
cancer as a large proportion of cancers are discovered at an incurable stage. A 
number of studies have investigated the clinical potential of novel tumor markers in 
disease stratification, progress monitoring and prognostication. A cancer biomarker 
can be any cellular, biochemical, molecular or genetic alterations indicating the 
presence of the tumor in the body. It can be tumor-derived DNA, RNA and protein 
which is present in a detectable form in circulation (Hanash et al, 2008; Marrero & 
Lok, 2004). Current noninvasive markers in clinical use for cancer diagnosis are 
mainly proteins that are secreted by tumor cells. However, only a subset of cancers 
produce specific proteins that are detectable in the circulation (Chan & Lo, 2007). 
RNA has also been studied through microarray analysis but its use as a biomarker is 
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limited by its relative instability of RNA compared with DNA in circulation. 
Therefore, the chemical and biological stability of DNA makes it appealing to be 
developed as cancer biomarkers (Tollefsbol, 2009). One of the most widely studied 
approach to detect circulating tumoral DNA is based on the detection of promoter 
hypermethylation of TSGs. Advances in molecular technology have provided various 
approaches for the sensitive detection of DNA methylation patterns and opened up 
the potential of utilizing circulating methylated DNA as cancer biomarkers. 
2.5.1. Methods for the analysis of DNA methylation markers 
Bisulfite conversion and methylation-sensitive restriction enzyme digestion are the 
two most commonly used methods for studying DNA methylation in different tissues 
(Frommer et al, 1992; Mcclelland, 1981). Restriction landmark genomic scanning 
(RLGS) is one of the earliest methods for studying genome-wide DNA methylation 
patterns (Costello et al, 2000). DNA is digested by methylation-sensitive restriction 
enzymes and subsequently radioactive-labeled on unmethylated CpG sites, then 
subjected to size-fractionation in one dimension using gel electrophoresis. Next, a 
second enzyme specific for a high-frequency target is added to the products, and the 
fragments are separated in another dimension to produce a group of scattered 
methylation hot-spots. The hot-spot pattern is compared between normal and tumor 
samples so that the frequency and location of methylated sites can be revealed by the 
position and intensity of the spots. 
The invention of bisulfite-conversion has revolutionized the analytical methods used 
for DNA methylation analysis. Sodium bisulfite can convert unmethylated cytosines 
to uracils while the methylated cytosines remain unaffected (Frommer et al, 1992). 
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Bisulfite genomic sequencing (Frommer et al, 1992)，combined bisulfite restriction 
analysis (COBRA) (Xiong & Laird, 1997) and methylation sensitive single 
nucleotide primer extension (Ms-SNuPE) (Gonzalgo & Jones，1997) utilize primers 
that do not cover any potential methylated sites and determine the methylation status 
of the region by analyzing the sequences within the amplicon (Laird, 2003). The 
development of methylation-specific PCR (MSP) (Herman et al, 1996) has greatly 
enhanced the study of DNA methylation as it allows the detection of aberrant DNA 
methylation in small amounts of DNA template obtained from clinical samples. The 
design of a MSP primer set is to amplify specifically the methylated DNA or 
unmethylated DNA in bisulfite-treated samples. Quantitative analysis of methylated 
sequences by real-time MSP (Lo et al, 1999) and Methylight (Eads et al, 2000) have 
also been developed. 
2.5.2. Detection of tumor-associated methylated DNA in the circulation of cancer 
patients 
The detection of tumor-derived aberrant DNA methylation has evolved as a new 
approach for cancer detection. In addition to detecting such aberrant methylation in 
tumor tissues, detection of such sequences in other biological samples, in particular 
plasma/serum has been attempted. However, the detection of tumor-associated 
aberrantly methylated TSG sequences in plasma/serum is technically challenging 
because these sequences are typically present at very low concentrations (Wong et al, 
2003) and among a high concentration of background wild-type sequences derived 
mainly from blood cells (Jahr et al, 2001). 
In earlier studies, MSP-based methods have been applied for detecting these 
— — 
Hypermethylation of tumor suppressor genes in cancer 
tumor-derived methylated sequences in the circulation of cancer patients. For 
example, methylated pl6 (Wong et al, 2003) and RASSFIA (Yeo et al, 2005) 
sequences were detected in the circulation of HCC patients. Methylated GSTPl 
sequences were detected in the circulation of prostate cancer patients (Goessl et al, 
2000). Methylated APC sequences were detected in esophageal cancer patients 
(Kawakami et al, 2000). Methylated DAPK sequences were detected in the serum of 
breast cancer patients (Dulaimi et al, 2004). As different types of cancers might have 
distinct profiles of aberrant TSG methylation, such profiles might be developed as 
specific tumor markers for certain cancers. Moreover, the combination of different 
TSG methylation markers might be useful for more sensitive cancer detection. 
It was reported that the pattern of CpG island methylation of a cancer was 
tumor-specific (Costello et al, 2000) and a number of aberrantly methylated tumor 
suppressor genes are frequently observed in HCC tissues. TSGs that are commonly 
methylated in HCC include pl6INK4A (Lo et al, 1999; Wong et al, 1999; Wong et al, 
2003), RASSFIA (Honda et al, 2008; Yeo et al, 2005; Zhong et al, 2003)，GSTPl (Su 
et ah 2007; Yang et al, 2003; Zhong et al, 2002)，APC (Nishida et al’ 2008; Nishida 
et al, 2007; Yang et al, 2003) and SOCSl (Miyoshi et al, 2004; Nagai et al’ 2002; 
Yoshikawa et al, 2001). The functions of these genes are discussed in more detail 
below. 
Glutathione S-transfterase Pi (GSTPl) is one of the members of the glutathione 
S-transferase family which protects cells against cytotoxic and carcinogenic agents 
like oxidants and electrophilic carcinogens (Mannervik et al, 1985). It catalyzes the 
conjugation of glutathione with electrophilic carcinogens and produces less cytotoxic 
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and more readily excreted metabolites (Zhong et al, 2002). Accumulation of 
electrophilic metabolites after the loss in GSTPl had been observed in prostate and 
resulted in DNA damage and mutation (Lee et al, 1994). As the liver is functioning 
as a detoxifying organ of the body, loss of GSTPl may further facilitate the exposure 
of toxic metabolites to hepatocytes and enhance the transformation of hepatocytes by 
tumor inducers (Su et al, 2007). In HCC, the methylation frequency of GSTPl in 
tumor tissue ranges from 41% to 88.5% (Lee et al, 2003; Su et al, 2007; Wang et al, 
2006; Zhang et al, 2005; Zhong et al, 2002). 
Suppressor of cytokine signalling-1 (SOCSl) is a member of SOCS protein family 
which is a negative regulator of the Janus kinase (JAK) and the signal transducer and 
activators of signaling (STAT) pathways. It binds to JAK directly or indirectly and 
inhibits the phosphorylation of STAT and downregulates the expression of target 
genes (Starr et al, 1997). In HCC, the previously reported methylation frequency of 
SOCSl in HCC tissue ranges from 41% to 65% (Miyoshi et al, 2004; Okochi et al, 
2003; Yang et al, 2003; Yoshikawa et al, 2001). 
Adenomatous polyposis coli (APC) is a negative regulator of the Wnt signaling 
pathway and is also involved in cell migration and adhesion, transcriptional 
activation, and apoptosis. Loss of APC results in accumulation of (3-catenin and 
interaction with the lymphoid enhancer factor-T cell factor (LEF-TCF) family of 
transcription factors and promotes the cells to enter the cell cycle (Csepregi et al, 
2008). Hypermethylation of APC is very common in HCC with high methylation 
frequency in tumor tissues ranging from 53% to 88.3% (Csepregi et al, 2008; Katoh 
et al, 2006; Lee et al, 2003; Nishida et al, 2008; Yang et al, 2003). 
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pl6INK4a (cyclin-dependent kinase inhibitor 2A, pi6) is one of the cell cycle 
regulator and inhibits the proliferation of normal cells by binding to CDK4 and 
CDK6. It prevents the interaction of CDK4 and CDK6 with cyclin D and hence also 
prevents the phosphorylation of retinoblastoma protein (pRb) and results in 
inactivation (Azechi et al, 2001; Maeta et al, 2005). The hypermethylation of pl6 is 
widely studied and the methylation frequency was observed from 16 to 79.5% 
(Katoh et cd, 2006; Lee et al, 2003; Nishida et al, 2008; Su et al, 2007; Wong et al, 
1999; Yang et al, 2003; Zhang et al, 2007). 
Most studies have used MSP as the technique to detect hypermethylated tumor 
suppressor genes in plasma or serum. However, a wide range of sensitivities of 
approximately 20-80% is observed whereas the reported frequency of 
hypermethylation in HCC tissues is 50-90%. It is believed that the sodium bisulfite 
treatment in MSP that leads to substantial degradation of DNA (up to 96%) (Grunau 
et al, 2001) and the presence of low concentrations of circulating tumor DNA in 
cancer patients are the reasons for the unsatisfactory detection rate of such sequences 
in plasma/serum (Chan et al, 2008a; Chan & Lo, 2007). 
Recently, a non-bisulfite-based technique termed methylation-sensitive restriction 
enzymes mediated real-time quantitative PGR was developed to detect methylated 
RASSFIA sequences quantitatively in maternal plasma (Chan et al, 2006a) and the 
plasma of HCC patients (Chan et al, 2008a). Although this technique showed a 
substantial improvement of detection rate in HCC of 93%, low concentrations of 
methylated RASSFIA were also detected in chronic HBV carriers. Thus, for HCC 
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surveillance purpose, it is hoped that one could further enhance the specificity of this 
approach. 
2.6. Aim of thesis 
To date, the measurement of serum AFP level and the imaging of liver by ultrasound 
represent the most common regimen for HCC detection. Low diagnostic accuracy of 
the diagnostic approach prompts researchers to search for more accurate markers for 
early HCC detection which can eventually improve the clinical outcomes and 
survival rates. 
Aberrant methylation of tumor suppressor genes has been found in the plasma/serum 
of patients with different cancers (Laird, 2003). Multiple markers have been shown 
to enhance the detection rates (Hoque et al, 2006). In this thesis, I developed a panel 
of methylated markers including GSTPl, SOCSI, APC and pl6 that involved in 
multiple cellular pathways by methylation-sensitive restriction enzymes mediated 
real-time PGR for the detection of HCC. 
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Chapter 3: Methods for detecting DNA methylation 
3.1. Subject recruitment 
Fifty-six HCC patients were recruited with informed consent from the Department 
of Surgery, Prince of Wales Hospital, Shatin, Hong Kong. The diagnosis of HCC 
was histologically confirmed. Six milliliters of peripheral blood were collected into 
two ethylenediaminetetraacetic acid (EDTA) tubes from each patient. A total of 90 
blood specimens were obtained from the 56 HCC patients of which 56 were 
collected 1 hr before surgical resection of the tumor and 34 were at one month 
postoperatively. Fifty-five chronic carriers of hepatitis B virus (HBV) infection and 
58 healthy volunteer with matched age (within 5 years) and sex were recruited as 
controls. 
3.2. Sample collection and processing 
3.2.1. Tumor tissue samples 
The tumor tissues were fresh frozen in liquid nitrogen immediately after collection 
and stored at -80°C until further analysis. 
12.2. Peripheral blood samples 
The blood samples in EDTA tubes were processed within six hours after collection 
(Chan et al, 2005a). They were centrifuged at 1,600 g for 10 min at 4°C (Centrifuge 
581 OR, Eppendorf, Hamburg, Germany) to separate plasma and blood cell layers. 
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Plasma was then carefully transferred to a 2 mL polypropylene tubes and 
microcentrifuged at 16,000 g for 10 min at 4°C (Centrifuge 5415R, Eppendorf) 
(Chiu et al, 2001). The supernatant was transferred to a new 1.5 mL polypropylene 
tube and stored at -20°C. The buffy coat was recentrifuged at 2,500 g for 5 min at 
room temperature. Residual plasma was removed and the sample was stored at 
-20�C. 
3.3. DNA extraction 
3.3.1. Plasma samples 
DNA was extracted from the plasma samples using the QIAamp DSP DNA Blood 
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturers' protocol. 
Briefly, 800 |iL of plasma sample was processed and split into two tubes of 400 \iL 
plasma each time to facilitate the extraction process. 400 pL of plasma was added to 
40 jiL of Qiagen protease and 400 |iL Lysis buffer was added subsequently. The 
lysate was vortexed and incubated at 56°C for 10 min. 400 [lL chilled 100% ethanol 
was added and mixed to precipitate the DNA. The lysate was processed by either the 
spin protocol or the vacuum protocol provided by manufacturer. For the spin 
protocol, the column was placed in a collection tube and centrifuged at 16,000 g for 
1 min until all the lysate passed through the membrane. Five hundred microliters of 
the AWl wash buffer were added and centrifuged at 16,000 g for 1 min to wash the 
column. This process was repeated except that the AWl buffer was replaced by the 
AW2 buffer. The column was centrifuged again at 16,000 g for 2 min to remove any 
residual buffer to avoid carryover to downstream analysis. For the vacuum protocol, 
the column was inserted into the VacConnector (VC) on the vacuum system. Six 
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hundred microliters of the lysate were then added to the QIAamp Mini Spin column. 
This process was repeated until all lysate of a particular sample has been loaded onto 
the colulmn. The main vacuum valve was open and the lysate was sucked by the 
vacuum to pass through the membrane and drain into the vacuum manifold. The 
column was then washed with the AWl and AW2 buffer sequentially. Next, the 
column was placed into a collection tube and centrifuged at 16,000 g for 2 min to 
remove any residual buffer. DNA was eluted with 50 jiL distilled water and stored at 
-20°C. 
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Figure 3.3.1. The extraction procedure by QIAamp DSP DNA blood mini kit 
(Adapted from Qiagen's kit manual) 
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3.3.2. Blood cells 
Blood cell DNA was extracted using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer's spin protocol. 400 [iL of blood cells was 
added to 40 |jL of Qiagen protease and 400 |jL Lysis buffer was added afterwards. 
The lysate was vortexed and incubated at 56°C for 10 min. 400 |j.L chilled 100% 
ethanol was added and mixed to precipitate the DNA. The entire lysate was then 
transferred to a QIAamp Mini Spin column which was placed in a collection tube 
and centrifuged at 16,000 g for 1 min until all the lysate passed through the 
membrane. 500 pL AWl and AW2 wash buffer were added and centrifuged at 
16,000 g for 1 min to wash the column subsequently. The column was centrifuged 
again at 16,000 g for 2 min to eliminate any residual buffer to avoid inhibition or 
contamination of the downstream assay. DNA was eluted twice with 50 |iL distilled 
water and stored at -20°C. 
3.3.3. Tumor tissue 
Tissue DNA was extracted using a QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer's tissue protocol. A small piece of tumor 
tissue was lysed with 180 fxL buffer ATL and 20 |iL proteinase K at 56°C overnight 
on a rocking platform. The lysate was then incubated with 200 i^L at 70°C for 10 
min. 200 |iL chilled 100% ethanol was added and mixed to precipitate the DNA. The 
entire lysate was then transferred to a QIAamp Mini Spin column which was placed 
in a collection tube and centrifuged at 16,000 g for 1 min until all the lysate passed 
through the membrane. Five hundred microliters of AWl wash buffer were added 
and centrifuged at 16,000 g for 1 min to wash the column. Then, this process was 
repeated with the AWl buffer replaced by the AW2 buffer. The column was 
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centrifuged again at 16,000 g for 2 min to eliminate any buffer carryover to avoid 
inhibition or contamination of the downstream assay. DNA was eluted twice with 50 
\iL distilled water and stored at -20°C. 
3.4. Quantitative analysis of methylated DNA using methylation-sensitive 
restriction enzyme-mediated real-time quantitative PCR (MSRE-qPCR) 
3.4.1. Methylation-sensitive restriction enzyme-mediated real-time quantitative 
PCR 
MSRE-qPCR is a non-bisulfite-based method for detecting hypermethylated DNA in 
a sample (Chan et al, 2008a). The DNA samples were first subjected to 
methylation-sensitive restriction enzymes (MSRE) digestion before real-time PCR 
(qPCR). When the cytosine residue of a MSRE recognition site is methylated, the 
digestion by the MSRE is blocked, thus, leaving an intact DNA template for 
downstream PCR amplification. However, if the cytosine is not methylated, the 
sequence is cut and no amplification of the target would be resulted (Figure 3.4.1). 
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Step 1: Methylation-sensitive restriction enzymes digestion on promoter region 
Unmethylated DNA Methylated DNA 
5. C^GC 3. 5： GCeC -3： 
3. CG<^  5. 3 CG^ 5 
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Step 2: Real-time quantitative PCR 
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Figure 3.4.1. Schematic diagram of MSRE-qPCR 
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3.4.2. Principle of real-time quantitative PCR 
Real-time quantitative polymerase chain reaction (real-time PCR / qPCR) is a 
modification of conventional polymerase chain reaction (PCR) and allows the 
quantification of the initial amount of the target DNA in the sample. The original 
real-time PCR was performed with the addition of a fluorescence dye binding 
specifically to double-stranded DNA, for example ethidium bromide or SYBR 
Green I. The intensity of the fluorescent signal would increase with the amount of 
double-stranded DNA formed. However, this method cannot differentiate the 
amplification of the desired product from non-specific amplification. To overcome 
this problem, TaqMan Probe-based technology was developed (Gibson et al, 1996). 
This method involves a dual-labeled single-stranded oligonucleotide probe with a 
fluorescent reporter dye on the 5' end and a quencher on the 3’ end. If the probe 
remains intact, the reporter and quencher are close to one another and the 
fluorescence emitted by the reporter is reduced by fluorescence resonance energy 
transfer (FRET). On the other hand, if the target sequence is present, the probe 
annealing to it is cleaved by the 5' nuclease activity of the Taq DNA polymerase 
during extension. This cleavage separates the reporter from the quencher and results 
in an increase in fluorescence signal. The fluorescence signal intensity generated 
would be proportional to the amount of the amplicons produced and hence reflects 
the quantity of the nucleic acid target. 
3.4.3. Real-time PCR primer design 
There are several steps for designing real-time assays for quantitative analysis of 
methylated DNA in the plasma of HCC patients. First, I identified the appropriate 
targets which are the promoter regions of tumor suppressor genes that are frequently 
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methylated in HCC. After identifying the appropriate tumor suppressor genes, 
restriction maps of their promoter regions were constructed to show the restriction 
sites of common methylation-sensitive restriction enzymes using the UCSC Genome 
Browser (University of California, Santa Cruz). 
Using these restriction maps, I identified regions that contain four or more 
restriction sites within 200 bp. The presence of four or more restriction sites within a 
PCR amplicon can increase the chance of cutting an unmethylated sequence whereas 
the length requirement is to increase the sensitivity of detecting tumoral DNA in 
plasma as these sequences have been shown to be predominantly below 200 bp 
(Chan & Lo, 2006). 
After the design of the real-time PCR systems for detecting the methylated TSG, 
assays for ascertaining the completeness of restriction enzymes digestion were also 
developed. These assays were designed on the promoter of the [3-actin gene {ACTB) 
which was previously reported to be completely unmethylated. The control assays 
had similar amplicon lengths and number of restriction sites as the corresponding 
TSG assays. If the enzyme digestion is complete, the unmethylated ACTB sequences 
should not be detectable and the result of the TSG detection would be used for 
further analysis. On the other hand, the presence of detectable unmethylated ACTB 
sequences would indicate incomplete digestion and the enzyme digestion step would 
need to be repeated. 
In this thesis, real-time PCR assays are named by their gene names such as GSTPl, 
SOCSl, APC and pl6\ and for the internal control assays, they are named as 
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P-actin*gstpl control, P-actin*socsl control, P-actin*apc control and p-actin*pl6 
control to represent the internal control amplicon/assay of GSTPl, SOCSl, APC and 
pl6 assay, respectively. 
One mock digestion control using genomic DNA from healthy individual was 
included in each round of digestion to ensure the digestion condition was normal. 
The final optimized digestion conditions are listed in table 3.4.2. 
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Table 3.4.1. Number of restriction sites in each assay 
Combination of Total no. of 
Amplicon ‘ � • � 
restriction enzymes restriction sites 
Target 6 
GSTPl *Bshl236I+HinplI 
Actin control 7 
Target 10 
SOCSl Bshl236I+HinpJI 
Actin control 9 
Target 6 
APC Acil+HinplI 
Actin control 5 
, , Target 5 
pi 6 Acil 
Actin control 4 
* HinplI and Acil were supplied by New England Biolabs and Bsh 12361 was from 
Fermentas. 
Table 3.4.2. Summary of the digestion conditions 
GSTPl SOCSl 
lOx NEB buffer 4 Ix 1 Ox NEB buffer 4 Ix 
HinplI 12 U HinplI 10 U 
Bshl236I 12 U Bshl236I 10 U 
Plasma DNA or 50 ng ^ Plasma DNA or 50 ng 
20|aL b 20 uL 
tissue DNA tissue DNA 
Water 0.1 i^L Water 0.5 ^L 
Total volume 25 jiL Total volume 25 jiL 
Incubation time 16 hrs Incubation time 16 hrs 
APC pl6 
lOx NEB buffer 3 Ix lOx NEB buffer 3 2.8 |iL 
Acil 60 U 
Acil 40 U 
HinplI 60 U 
Plasma DNA or 50 ng Plasma DNA or 50 ne 
20|iL 5 20 uL 
tissue DNA tissue DNA 
Total volume 35.5 pL Total volume 26.8 |iL 
Incubation time 16 hrs Incubation time 28 hrs 
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3.4.4. Duplex real-time PCR 
Duplex real-time PCR was used to co-amplify the target genes and the internal 
control. This approach enabled the simultaneous detection of the internal control 
ACTB and the target TSG sequences in a sample such that the enzyme digestion 
efficiency of a particular sample can be accurately analyzed. Moreover, this design 
can also improve the robustness of the analysis and reduce the reagent cost. In my 
study, TaqMan probes with non-fluorogenic quenchers (NFQ) were used. The 
advantage of non-flourogenic quenchers compared with fluorogenic quenchers e.g. 
TAMRATm (6-carboxyteramethylrhodamine) include a lower background noise and 
better sensitivity. Probes labeled with FAM™ (6-carboxyfluorescein) (>tmax= 518 nm) 
are used in assays detecting the methylated TSGs and probes labeled with VIC® 
(?tmax = 554 nm) are used in the digestion control assays. A standard curve of 
calibrators ranging from 10,000 copies per 5 |iL to 2.4 copies per 5 |iL was prepared 
by serial dilutions of a known quantity of human blood cell DNA from a healthy 
control sample. All the real-time PCR assays were performed using an Applied 
Biosystems 7300 Sequence Detector (Applied Biosystems, Foster City, CA). All 
sample wells in a sealed 96-well plate were illuminated with a tungsten-halogen 
lamp and the fluorescence emission was detected through four filters onto a 
charge-coupled device (CCD) camera. ROX dye (X a^x = 610 nm) was used as 
passive reference to normalize for non-PCR-related fluctuations in fluorescence 
signal. The real-time PCR data were analyzed by the Sequence Detection System 
(SDS) Software vl.2.3 (Applied Biosystems, Foster City, CA). The threshold cycle 
(CT) was determined for each well and a standard curve was constructed by plotting 
the Ct against the quantity of the corresponding calibrators. 
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3.4.5. Real-time detection of GSTPl, SOCSl, APC, pi 6 and A CTB sequences 
Hypermethylated GSTPl, SOCSl, APC and pl6 sequences, together with the 
respective ACTB digestion control sequences were detected using the 
methylation-sensitive restriction enzymes-mediated real-time PCR. The assays were 
performed using the TaqMan® Universal PCR Master Mix (Applied Biosystems, 
Foster City, CA) in a total reaction volume of 50 |iL. The PCR Master Mix was 
optimized for TaqMan reactions and contained AmpliTaq Gold DNA polymerase, 
AmpErase UNG, dNTPs, passive reference ROX and optimized buffer components. 
The primer and probe concentrations for each assay were optimized with blood cells 
DNA from healthy individuals and universal methylated DNA (Chemicon) and were 
listed in table 3.4.4. The thermal profile of the real-time PCR was 50°C for 2 min, 
95°C for 10 min and 50 cycles of 95°C for 15 sec and 60°C for 1 min. All the 
samples were run in duplicates and the mean quantities were used for downstream 
analysis. No template controls were included in all reaction plates to detect any 
DNA contamination in reaction components. 
3.4.6. Statistical analysis of real-time PCR results 
Demographical information of HCC patients and HBV carriers were analyzed by the 
Student's t test, chi-square analysis and the Mann-Whitney U test. The 
concentrations of tumor suppressor genes in the plasma of HCC patients, HBV 
carriers and healthy controls were compared by the Kruskal-Wallis test. The 
methylated TSG concentrations of preoperative and postoperative plasma in HCC 
patients were compared using the Wilcoxon signed-rank test. The differences 
between survival curves were analyzed by the log-rank test and the associations 
between clinical parameters and TSG methylation with survival rates were analyzed 
— 
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using univariate and multivariate Cox regression analyses. Survival analyses were 
done by MedCalc version 9.6.4 and other statistical analyses were performed by the 
SigmaStat 3.5 software. 
Materials and methods 
Table 3.4.3. Primer and probe sequences of quantitative real-time PCR 




GSTP 1 -83 6R CTGG AGTCCCCGGAGTCG 
GSTP1-689T FAM-CCCGCGATGTC-NFQ 
SOCSI 
SOCS1 -1879F CGTTCGCACGCCGATTAC 
176 
SOCS 1-2053R CGCTAAGGGCGAAAAAGCA 
SOCS 1-2009T FAM-TGGTGCGCGACAG-NFQ 
APC 




pi6 2 OIF CTGGCTGGTCACCAGA 
H - - 98 
p 16_2_01R CCGGCTCC ATGCTGCTC 
pl6 一 2—OIT FAM-CGGACCGCGTGCGCT-NFQ 
p-actin*gstpl control 
actb-gstp 1-OlF GCGCCGTTCCGAAAGTT 
actb-gstp 1-OlR CGGCGGATCGGCAAA 
actb-gstp 1-OlT VIC-CCGAG ACCGCGTC-NFQ 
p-actin*socsl control 
actb-socs 1-OlF TTCGCCCGTGC AG AGC 
actb-socsl-OlR CGAGAGCGGCACCCC 口^ 
actb-socs 1-OlT VIC-AC ACCCC ACGCC AGTT-NFQ 
p-actin *apc control 
actb-apc-01F ACGGCTCCGGC ATGTG 
162 
actb-apc-OlR GGCTCCTGTGCAGAGAAAGC 
actb-apc-01T VIC-CCCC AGGC ACC AGGTA-NFQ 
p-actin *pl 6 control 
actb_pl6 2 OIF CCACGCCAGTTCGGAGG 
92 
actb_p 16_2_01R AG AGCCCGGCTC AGAC AAA 
actb_p 16—2—01T VIC-CTCGGGAGGCGCGCT-NFQ 
Notes 
F: Forward primer 
R: Reverse primer 
T: Fluorescent probe 
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Table 3.4.5. Thermal profile for qPCR analysis 
Times and Temperatures 
Each of 50 cycles 
Thermal Cycler 
First cycle Denaturation Anneal/Extend 
ABI Prism 7300 Sequence 
2 min 10 min 15 sec 1 min 
Detector 
50°C 95°C 95°C 60°C 
(Modified from TaqMan Universal PCR Master Mix Protocol) 
_ 
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3.5. Methylation study of GSTP1，SOCS1, APC, pl6 and ACTB in tumor 
tissues and blood cells using bisulfite sequencing 
3.5.1. Principle of bisulfite modification 
Bisulfite modification is widely used in methylation analysis, which utilizes sodium 
bisulfite to deaminate unmethylated cytosine to uracil while the 5-methylcytosine 
remains unchanged (Frommer et al, 1992). After bisulfite treatment and PCR, the 
methylation status of CpG sites can be determined. Bisulfite conversion works by 
reaction between cytosine and bisulfite ion to form a sulphonated cytosine derivative. 
The reaction is reversible and affected by the concentration of hydroxide, bisulfite 
ion and temperature. 
HH? 叫 9 0 
I I J ^ ^ m ^ p j J 
浙 m 够 o 人 N 入 S W 0、一 Z 
R R R ' R 
Cylos^ Uracil 
Figure 3.5.1. The chemical reaction of sodium bisulfite conversion of 
unmethylated cytosine 
(Adapted from http://www.dkfz.de/funct_genome/epigenetics-genotyping.html) 
A uracil-bisulfite derivative is formed after hydrolytic deamination. This reaction 
requires a catalyst like sulfite, bisulfite or acetate anions. Lastly, uracil is obtained 
by adding alkaline substances to remove the sulphonate group on the fifth carbon. 
This reaction can occur when cytosine is a free base, nucleoside (ribo- or 
deoxyribo-), nucleotide or oligonucleotide. After PCR amplification, the 
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unmethylated cytosine (appears as uracil) in the bisulfite-treated D N A is amplified 
as thymine while the methylated cytosine remains as cytosine. Hence, the 
methylation status of a sample can be determined by analyzing the sequence of the 
bisulfite-converted D N A . 
3.5.2. Bisulfite conversion 
Bisulfite conversion of D N A samples were performed using the EZ D N A 
Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer's 
protocol. Five microliters of the M-Dilution Buffer were incubated at 37°C for 15 
min with 1 pg of tissue D N A or blood cells D N A after adjusting to a total volume of 
50 (IL with deionized water. Then the sample was mixed with 100 jiL freshly 
prepared CT Conversion Reagent and incubated in the dark at 56°C for 16 hr. The 
sample was subsequently cooled on ice for 10 min. Four hundred microliters of 
M-Binding Buffer was mixed with the sample and the mixture was loaded onto a 
Zymo-Spin IC Column and centrifuged at 13,000 rpm for 30 s. 100 |iL of M-Wash 
Buffer was added to wash the column which was then centrifuged at full speed for 
30 s. Then 200 [iL of M-Desulphonation Buffer was loaded to the column and 
followed by incubation at room temperature for 15 min. After centrifugation at full 
speed for 30 s, 200 (J.L M-Wash Buffer was added twice sequentially to wash away 
the residual buffer. Finally, the bisulfite-converted D N A was eluted with 25 [iL of 
1:1 mixture of M-Elution Buffer and deionized water. 
3.5.3. Sequencing primer design 
As the aim of bisulfite sequencing was to build the foundation for testing the 
capability of real-time PCR assay in reflecting the actual methylation status in tumor 
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tissue and bood cells, the bisulfite PCR was designed to sequence the regions 
corresponding to the amplicons of the real-time PCR assays. In addition, owing to 
the limitation in sequencing that the first and last 50-100 bp of the PCR amplicon is 
usually not able to be sequenced or at a very low resolution, therefore, the bisulfite 
PCR was designed from 100 bp upstream to 100 bp downstream of the amplicon if 
possible in order to obtain the complete sequences. As the two parental D N A strands 
are no longer complementary to each other after bisulfite conversion, suitable 
primers may be obtained from the sense or antisense strand. The design of bisulfite 
PCR primers was done manually and with the aid from three programs, namely 
MethPrimer (http://www.urogene.org/methprimer/index 1 .html), Bisearch 
(http://bisearch.enzim.hu/), and Primer Express 3.0 (Applied Biosystems). 
The final primer sequences were determined after considering following factors: 
(i) The forward and reverse primers §houId hive §imilar melting temperatures to 
facilitate PCR optimization. 
(ii) The primer-dimer and secondary structure of primers should be absent, if 
possible. 
(iii) As the proportion of thymine (T) in the genome increases greatly after 
bisulfite conversion and may result in many continuous T, the chances of 
non-specific annealing and amplification of non-specific products are 
enhanced. Therefore, the primers was checked by the ePCR program in 
Bisearch to see if there is any non-specific products amplified by the primers 
in the bisulfite converted genome in silico. 
(iv) CpG sites are avoided in the primer sequences to minimize biases in 
amplifying methylated or unmethylated D N A . 
In this thesis, bisulfite sequencing assays were named by bis-gene name, such as 
_ 
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bis-GSTPl, bis-SOCSl, bis-APC and bis-pl6. For the sequencing of internal control 
amplicons, as the four real-time PCR assays were designed towards the ACTB gene 
and in proximity to each other, therefore, one assay named Actin—GPS was designed 
to sequence the amplicons (3-actin*gstpl control, p-actin*pl6 control and 
p-actin*socsl control, and another assay named Actin APC was to sequence the 
p-actin*apc control. 
3.5.4. Conventional PCR after bisulfite treatment 
The bisulfite-treated D N A was amplified by conventional PCR using the AmpliTaq 
Gold polymerase and the GeneAmp PCR Core Reagent Kit (Applied Biosystems) in 
a total volume of 25 jiL for bis-GSTPl, bis-SOCSl, bis-APC, bis-pl6 and 
Actin—APC assays. For the Actin—GPS assay, HotStarTaq D N A Polymerase and the 
provided reagents (Qiagen, Hilden, Germany) was mixed in a total volume of 10 jjL. 
To the former assays, corresponding primers, IX PCR Buffer II’ 3 m M of MgCb, 
200 ^ M of dNTP mix (Promega, Madison, WI) and 1.25 U AmpliTaq Gold 
polymerase were added with 2 jjL of bisulfite-treated DNA (except in bis-pl6 
amplification, 2.5 m M MgCl 2 was used). For the Actin_GPS assay, IX HotStar 
Buffer and corresponding primers, 1 m M MgCl 2, 200 \iM of dNTP mix and 0.4 U of 
HotStarTaq polymerase were mixed with 1 jiL bisulfite-treated D N A . The thermal 
profile for the assay using GeneAmp PCR Core Reagent kit was 95°C for 10 min, 
followed by denaturation at 95°C for 40 s, annealing at corresponding temperatures, 
and extension at 72°C for 40 s for 40 cycles and a final incubation at 72°C for 10 
min. The thermal profile for the assay using the HotStarTaq polymerase was 94°C 
for 15 min to activate the polymerase, and followed by denaturation at 94°C for 20 s, 
annealing at 59°C for 30 s, and extension at 72°C for 1 min for 45 cycles and a final 
49 
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3.5.5. Cloning and bisulfite genomic sequencing 
After PCR amplification, the products were cloned for subsequent sequencing using 
the pGEM®-T Easy Vector System (Promega, Madison, WI). The ligation was done 
by mixing IX Rapid Ligation Buffer, 50 ng pGEM®-T Easy Vector, 3 Weiss units of 
T4 D N A Ligase and 3 jjL PCR products and incubated at 16°C overnight. As the 
AmpliTaq Gold polymerase and the HotStarTaq polymerase generate an extra 
A-overhang in PCR products during PCR, the vector has a 3'T-overhang to provide 
a compatible end for ligation and also prevent the vector to re-circularize. 
The transformation was started by incubating 10 |j,L of ligation products with 60 \iL 
of the Escherichia coli strain JM109 High Efficiency Competent Cells (Promega) on 
ice for 30 min. Heat-shock was performed at 42°C for 1 min followed by 2 min 
chilling on ice. 260 (j,L SOC (Super Optimal broth with Catabolite repression) 
medium (Invitrogen, Carlsbad, CA) was added to recover the cells. The cells were 
incubated at 37°C for 1.5 hr with shaking. As the cloning site of the pGEM®-T Easy 
Vector is within the a-peptide coding region of the enzyme p-galactosidase, this 
allows blue-white screening to pick up the recombinant clones later on. After the 
cells were centrifuged at 1,000 g for 10 min and resuspended in 100 jiL SOC 
Medium, 40 X-Gal and 20 \iL IPTG were added to each sample and plated onto 
LB/ampicillin plates. The plates were incubated overnight at 37°C. 
Sixteen white recombinant colonies were picked from each sample plate into 10 pL 
deionized water and lysed at 95°C for 3 min. The plates were stored at 4°C for later 
use, if needed. Then a colony PCR using the SP6 and T7 R N A polymerase 
promoters as primers was performed. The sequences of SP6 and T7 primers are 
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5'-ATT T A G G T G A C A CTA T A G AA-3' and 5'-TAA T A C G A C T C A CTA T A G 
GG-3' (Proligo). In a total volume of 12.5 ^ L, IX Buffer II，2.5 m M MgCl 2, 200 ^ iM 
dNTP mix, 100 n M of SP6 and T7 primers and 1.25 U of AmpliTaq Gold 
polymerase were added with 1.5 (iL colony D N A template solution. The PCR was 
started at 95°C for 10 min, followed by denaturation at 95°C for 40 s, annealing at 
55°C for 1 min and extension at 72°C for 40 s for 30 cycles and a final incubation at 
72°C for 7 min. 
Gel electrophoresis was run to confirm the presence of insert by checking the size of 
D N A band. Cycle sequencing reaction was performed afterwards using BigDye 
Terminator Cycle Sequencing version 1.1 Kit (Applied Biosystems). In a 10 p,L 
reaction, 2 |iL Ready Reaction Premix, IX BigDye Sequencing Buffer, 160 n M 
sequencing primer (SP6 primer) and 1 p,L template of the cloned P C R product were 
mixed together. The thermal profile was 96。C for 30 s, 50°C for 15 s and 60。C for 4 
min for 25 cycles. The products were precipitated by ethanol/sodium acetate method 
and denatured with 10 \xL of HiDi Formamide (Applied Biosystems) at 95°C for 3 
min. Samples were then sequenced using the ABI PRISM® 3100 Genetic Analyzer 
(Applied Biosystems). 
3.5.6. Data acquisition and interpretation 
The fluorescence data were collected and interpreted by the ABI PRISM® 3100 
Genetic Analyzer Data Collection Software vl.0.1 which displayed the data as an 
electropherogram. The sequences were analyzed by aligning to the template 
sequences using the Seqscape Software and the methylation status of CpG sites were 
scored manually. Eight clones were selected from each sample according to their 
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sequencing quality determined by the Seqscape Software and the completeness of 
alignment to the target amplicons. As mentioned in Chapter 3.5.1，after bisulfite 
conversion, unmethylated cytosine would change to thymine while methylated 
cytosine would remain as cytosine. The methylation status of all clones from 
sequencing was illustrated as dot diagrams. A closed circle represented a methylated 
cytosine in a CpG site and an open circle represented an unmethylated cytosine in a 
CpG site. Details are discussed in Chapter 4.2. 
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Chapter 4: Evaluation of the real-time PCR assay for 
quantification of methylated tumor suppressor genes 
4.1. Development of real-time PCR assays 
The quantification of tumor suppressor genes was performed by a duplex real-time 
PCR system described in chapter 3. The use of a standard curve in real-time PCR 
allowed the absolute quantification of nucleic acids by amplifying the serially 
diluted calibrators derived from buffy coat D N A from normal individuals. The 
calibration curves were designed to amplify specifically for the sequences of GSTP1, 
SOCS1, APC and pl6 and their corresponding ACTB regions in each assay. The 
concentrations of the calibrators were from 10,000 copies to 2.4 copies, in all 
amplification systems. For the GSTP1 calibration curve, the slope was -3.64 and 
correlation coefficient (R ) was 0.997. For the SOCS1 calibration curve, the slope 
was -3.81 and correlation coefficient (R2) was 0.990. For the APC calibration curve, 
the slope was -3.94 and correlation coefficient (R2) was 0.997. Finally, for the pl6 
calibration curve, the slope was -3.74 and correlation coefficient (R2) was 0.991 
(Table 4.1.1). As mentioned in Chapter 3，an internal control system amplifying a 
region in the ACTB gene (specifically designed for each amplicon) was also 
co-amplified in the real-time PCR of each TSG to indicate the completeness of 
enzyme digestion. For the internal control for GSTP1 (P_actin*gstpl control), the 
slope of calibration curve was -3.66 and the correlation coefficient (R2) was 0.986. 
And for the internal control for SOCS1 (P-actin*socsl control), the slope of 
Development of methylation markers in HCC detections 
calibration curve was -4.68 and the correlation coefficient (R ) was 0.907. For the 
internal control of APC (p-actin*apc control), the slope of calibration curve was 
-3.73 and the correlation coefficient (R2) was 0.987. Finally, for the pl6 
(p-actin*pl6 control), the slope of calibration curve was -4.23 and the correlation 
coefficient (R2) was 0.975 (Table 4.1.1 and Figure 4.1.1). The PCR efficiencies of 
the standard curve in duplex real-time PCR had been optimized as high as possible. 
The PCR efficiencies of the amplification of target genes ranged from 79.4% to 
88.2% and the PCR efficiencies of the amplification of internal control ranged from 
63.6% to 87.6%. 
Table 4.1.1. The slope, PCR efficiency and correlation coefficient of the calibration 
curves in real-time PCR assays 
Correlation 
Assay Slope PCR efficiency 
coefficient (R2) 
GSTP1 -3.64 88.2% 0.997 
(3-actin*gstpl control -3.66 87.6% 0.986 
SOCS1 -3.81 83.0% 0.990 
P-actin*socsl control -4.68 63.6% 0.907 
APC -3.94 79.4% 0.997 
P-actin*apc control -3.73 85.4% 0.987 
pl6 -3.74 85.1% 0.991 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Development of methylation markers in HCC detections 
4.2. Methylation analyses by bisulfite sequencing were concordant with the 
real-time quantification results 
Methylation patterns of the GSTP1, SOCS1, APC, pl6 and ACTB genes in paired 
H C C tissue and blood cells were analyzed by bisulfite sequencing (Frommer et al, 
1992), to determine whether the real-time quantification assays were reflecting the 
methylation status in the tumor tissue and blood cells. Five pairs of tumor tissues 
and blood cells from H C C patients were studied. The methylation status of all clones 
determined by sequencing are illustrated as dot diagrams. Each row represents one 
D N A molecule and a total of eight clones were analyzed for each sample. The top 
row of a dot diagram represented the relative nucleotide position of the CpG sites to 
the transcriptional start site (+1). Negative numbers indicate locations upstream 
from the transcriptional start site. The data of one representative paired sample of 
tumor tissue and blood cells for each assay were shown in Figure 4.2.1. 
Among the five cases analyzed by bisulfite sequencing analysis, methylated GSTPJ 
sequences can be observed in all of the tumor tissues while most of CpG sites in 
blood cells were unmethylated. The corresponding ACTB sequences were 
unmethylated in both the tumor tissues and blood cells. The real-time analyses of the 
tumoral and blood cell D N A after restriction enzyme digestion showed concordant 
results with those using bisulfite sequencing analysis. GSTP1 sequences were 
detectable in all of the tumor tissue D N A but none of the blood cell D N A whereas 
ACTB sequences were not detectable in any of the digested tumor tissues nor blood 
cell D N A . 
6\ 
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In the bisulfite sequencing analysis for SOCS1, two out of five tumor tissues were 
hypermethylated while most of CpG sites in blood cells were unmethylated. Almost 
all of the CpG sites in the corresponding ACTB were unmethylated except one. The 
real-time analysis of the tumor and blood cell D N A after restriction enzyme 
digestion showed concordant results with bisulfite sequencing. After enzyme 
digestion, SOCS1 sequences were detectable in tumor tissues with aberrant 
methylation status and undetectable in tumor tissues without aberrant D N A 
methylation whereas none of the blood cells samples had detectable SOCS1 signal. 
The corresponding ACTB sequences were detectable in neither tumor tissue D N A 
nor blood cell D N A . 
In the bisulfite sequencing analysis for APC, four out of five tumor tissues were 
hypermethylated while none of the blood cells had methylated CpG sites. Almost all 
of the CpG sites in the corresponding ACTB were unmethylated except that some 
samples had one to two methylated CpG sites. Real-time analyses of the tumor 
tissues and blood cells D N A after restriction enzyme digestion showed concordant 
results with bisulfite sequencing. After enzyme digestion, APC sequences were only 
detectable in tumor tissues with aberrant methylation status whereas APC sequences 
were not detected in any blood cell D N A samples. The corresponding ACTB 
sequences were not detectable in any tumor tissue nor blood cell D N A . 
For the pl6 bisulfite sequencing analysis, two out of five tumor tissues were 
hypermethylated. On the other hand, the D N A samples from blood cells were 
generally unmethylated. The CpG sites in the corresponding ACTB region were 
generally unmethylated except the last CpG site (+340) was occasionally methylated. 
62 
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On the other hand, the real-time analyses of the tumor and blood cell D N A after 
restriction enzyme digestion showed concordant results with bisulfite sequencing. 
After enzyme digestion, pl6 sequences were only detectable in tumor tissues with 
aberrant D N A methylation whereas pl6 sequences were not detected in any of the 
blood cells samples. The corresponding ACTB sequences were not detectable in any 
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Clinical application of methylated markers in the detection of HCC 
Chapter 5: Clinical application of methylated markers in 
the detection of hepatocellular carcinoma 
5.1. Demographics of HCC patients and HBV carriers 
After evaluating the real-time PCR amplification systems for detecting methylated 
tumor suppressor genes, samples from HCC patients, HBV carriers and healthy 
individuals were analyzed to explore the clinical potential of these methylated 
markers. The HBV carriers had been followed for at least 18 months to confirm that 
they were free of HCC. Table 5.1.1 shows the demographic information of the HCC 
patients and HBV carriers. The age of the two groups of subjects were matched 
within 5 years and there is no statistically significant difference between them (t-test, 
P = 0.417). A male preponderance was shown in both groups with a proportion of 
male 87.5% and 80% in the HCC patients and in the HBV carriers, respectively 
(Chi-square test, P = 0.415). Ninety-one percent of HCC patients were HBV-infected. 
None of the HCC patients or the HBV carriers was HCV-infected. The proportions 
of HBV carriers with cirrhosis were not significantly different between the HCC 
patients and the HBV carriers. Fifty-five percent of the HCC patients and 9.1% of 
the HBV carriers had serum AFP level > 20 |ig/L and their median serum AFP levels 
are significantly different (Mann-Whitney test, p < 0.001). Table 5.1.2 shows that 
there are no statistically significant correlations between plasma concentrations of 
methylated tumor suppressor genes with tumor size except pi 6. 
- _ ^ 
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Table 5.1.1. Demographics of the HCC patients and HBV carriers 
HCC patients HBV carriers P-value 
Variable 
(n=56) (n=55) (univariate) 
Age (years) 55.5 (50-63)* 53 (50-59)* 0.417' 
Sex (% of male) 87.5% 80% 0.415^ 
Hepatitis B infection, n (%) 51 (91) 55 (100) NA 
Hepatitis C infection, n (%) 0 (0) 0 (0) NA 
Ultrasonographic evidence of 
23 (41.1) 31 (56.4) 0.155" 
cirrhosis, n (%) 
Serum AFP, fig/L 30 (4-159.25)* 4 (2.5-7)* <0.001� 
a t-test 
b Chi-square test 
e Mann-Whitney test 
* Data are represented by the median value (interquartile range) 
NA: Not applicable 
Table 5.1.2. Correlation of plasma concentrations of methylated GSTPl, SOCSI, 






*Spearman correlation analysis 
“ 70 
Clinical application of methylated markers in the detection of HCC 
5.2. Quantitative analysis of hypermethylated tumor suppressor genes in 
tumor and plasma samples 
Detection of hypermethylated GSTPL SOCSL APC and pl6 sequences after MSRE 
digestion for HCC tumor samples 
Among the 56 HCC tumor tissues, 44 (78.6%), 36 (64.3%), 49 (87.5%) and 50 
(89.3%) of them were methylated for the GSTPl, SOCSl, APC and pl6 genes, 
respectively (Table 5.2.1). Twenty-eight (50%) of the HCC patients had all 4 TSGs 
methylated in the tumor tissues, 25% of them had three methylated TSGs in their 
tumor tissues and 21.4% of them had two methylated TSGs in their tumor tissues. 
Only one patient had a single TSG methylated in the tumor, and one had all four 
TSGs completely unmethylated (Table 5.2.2). 
Table 5.2.1. Detection rates of methylated TSGs in HCC tumor tissues 
G No. of patients (n=56) 
with methylation in HCC tumor tissues n, (%) 
GSTPl 44 (78.6) 
SOCSl 36 (64.3) 
‘ APC 49 (87.5) 
pl6 50 (89.3) 
Table 5.2.2. Detection rates of multiple methylated TSGs in HCC tumor tissues 
No. of methylated markers No. of HCC patients (n=56) 
in tumor tissues n, (%) 
0 1 (1.8) 
- — 
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1 1 (1.8) 
2 12(21.4) 
3 14 (25.0) 
4 28 (50.0) 
Detection of hypermethylated GSTPl, SOCSL APC and pl6 sequences after MSRE 
digestion for the plasma samples of the HCC patients, HBV carriers and healthy 
individuals 
I evaluated the detection rate of methylated TSGs in the corresponding plasma 
samples for patients with such methylated TSGs in tumor tissues. Of the 44 HCC 
« 
patients with detectable methylated GSTPl in tumor tissues, 24 (54.5%) of them 
showed detectable methylated GSTPl sequences in plasma. Of the 36 HCC patients 
with detectable methylated SOCSl in tumor tissues, 20 (55.6%) of them showed 
detectable methylated SOCSl sequences in plasma. Of the 49 HCC patients with 
detectable methylated APC in tumor tissues, 18 (36.7%) of them showed detectable 
methylated APC sequences in plasma. Of the 50 HCC patients with detectable 
methylated pl6 in tumor tissues, 33 (66%) of them showed detectable methylated 
pl6 sequences in plasma. 
Table 5.2.3. Detection rates of methylated TSGs in the plasma of HCC patients with 
methylated TSGs in tumor tissues 
TSG (n = no. of patients 
. No. of HCC patients (with methylated TSG in tumor 
with methylated TSG in v j 
• � tissue) with methylated DNA in plasma n, (%) 
tumor tissue) 
GSTPl (n=44) 24 (54.5) 
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SOCSl (n=36) 20 (55.6) 
APC (n=49) 18(36.7) 
pl6(n=50) 33 (66.0) 
Methylation of multiple TSGs was also observed in the plasma samples of the HCC 
patients. Despite the percentage of patients having all 4 methylated markers was 
only 5.4%, the percentage of patients with 3, 2 or 1 methylated markers in plasma 
were 25%, 26.8% and 19.6% respectively. In 23.2% patients, no methylated TSG 
was detected in the plasma. 
Table 5.2.4. Detection rates of multiple methylated TSGs in plasma of HCC patients 
No. of methylated markers . No. of HCC patients (n=56) 
in plasma with methylation in plasma n, (%) 
0 13 (23.2) 
1 11(19.6) 
2 15 (26.8) 
3 14(25.0) 
4 3 (5.4) 
The overall detection rates of methylated TSGs sequences after enzyme digestion in 
the plasma of 56 HCC patients at diagnosis were 42.9%, 35.7%, 32.1% and 58.9% 
for the GSTPl, SOCSl, APC andp l6 sequences, respectively. For the HBV carriers, 
methylated GSTPl, SOCSl and pl6 sequences were detected in 3.6%, 3.6% and 
9.1%, respectively. Methylated APC sequences were not detectable in the plasma 
samples of any HBV carriers. Only two (3.4%) of the 58 healthy individuals showed 
— 
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detectable APC sequences. GSTPl, SOCSI and pl6 sequences were not detectable 
in any of the plasma samples from healthy individuals after digestions. 
(Kruskal-Wallis, P<0.001) 
Table 5.2.5. Detection rates of methylated TSGs in plasma samples of HCC patients, 
HBV carriers and healthy individuals 
No. of HCC patients No. of HBV carriers No. of healthy 
(n=56) with (n=55) with controls (n=58) with 
Gene 
methylated DNA in methylated DNA in. methylated DNA in 
plasma n, (%) plasma n, (%) plasma n, (%) 
GSTPl 24(42.9) 2(3.6) 0(0) 
SOCSI 20 (35.7) 2 (3.6) 0(0) 
APC 18(32.1) 0(0) 2(3.4) 
pl6 33 (58.9) 5 (9.1) 0(0) 
Overall, at least one of the four TSG sequences could be detected in the plasma of 
76.8% (43 of 56) of HCC patients, 14.5% (8 of 55) of HBV carriers and 3.4% (2 of 
58) of healthy individuals. 
Table 5.2.6. Detection rates of at least one hypermethylated TSG marker in the 
plasma of HCC patients, HBV carriers and healthy individuals 
No. of HCC patients No. of HBV carriers No. of healthy controls 
(n=56) with at least one (n=55) with at least one (n=58) with at least one 
methylated TSGs detected methylated TSGs detected methylated TSGs detected 
in plasma n，(%) in plasma n, (%) plasma n, (%) 
43 (76.8) 8 (14.5) 2 (3.4) 
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Figure 5.2.1. Plasma concentrations of methylated GSTPl (A), SOCSl (B), APC 
(C) andp l6 (D) sequences after enzyme digestion in the plasma of 56 HCC patients, 
55 HBV carriers and 58 healthy individuals 
76 
Clinical application of methylated markers in the detection of HCC 
5.3. Effect of cirrhosis on the plasma methylated tumor suppressor gene 
concentrations 
For both of the HCC patients and HBV carriers, subjects with and without 
ultrasonographic evidence of cirrhosis did not have significant difference in the 
plasma concentrations of each of the four methylated TSGs. 
For the HCC patients with cirrhosis, 12 of the 23 patients had detectable GSTPl 
sequence in their plasma, whereas 16 of the 33 HCC patients without cirrhosis had 
detectable GSTPl sequences in their plasma. The proportion of methylated GSTPl 
in plasma of HCC patients with and without ultrasonographic evidence of cirrhosis 
was not statistically different (Mann-Whitney test, P = 0.650). For the HBV carriers 
with cirrhosis, 2 of the 31 subjects had detectable GSTPl sequences in their plasma 
whereas none of the 24 HBV carriers without cirrhosis had detectable GSTPl 
sequences in their plasma. The proportion of methylated GSTPl in the plasma of 
HBV patients with and without ultrasonographic evidence of cirrhosis was not 
statistically significantly different (Mann-Whitney test P = 0.219). 
For the HCC patients with cirrhosis, 8 of the 23 patients had detectable SOCSl 
sequences in their plasma whereas 12 of the 33 HCC patients without cirrhosis had 
detectable SOCSl sequences in their plasma. The proportion of methylated SOCSl 
in plasma of HCC patients with and without ultrasonographic evidence of cirrhosis 
was not statistically significantly different (Mann-Whitney test, P = 0.863). For the 
HBV carriers with cirrhosis, 1 of the 31 subjects with detectable SOCSl sequences 
in the plasma whereas 1 of the 24 HBV carriers without cirrhosis had detectable 
— 
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SOCSl sequences in the plasma. The proportion of methylated SOCSl sequences in 
plasma of HBV patients with and without ultrasonographic evidence of cirrhosis was 
not statistically significantly different (P = 0.896，Mann-Whitney test). 
For the HCC patients with cirrhosis, 8 of the 23 patients had detectable APC 
sequences in their plasma whereas 10 of the 33 HCC patients without cirrhosis had 
detectable APC sequences in their plasma. The proportion of methylated APC in 
plasma of HCC patients with and without ultrasonographic evidence of cirrhosis was 
not statistically significantly different (Mann-Whitney test, P = 0.786). For HBV 
carriers with cirrhosis, none of the 31 patients had detectable APC sequences in their 
plasma whereas none of the 24 HBV carriers without cirrhosis had detectable APC 
sequences in their plasma. The proportion of methylated APC in plasma of HBV 
patients with and without ultrasonographic evidence of cirrhosis was not statistically 
different (Mann-Whitney test, P = 1.000). 
For the HCC patients with cirrhosis, 12 of the 23 patients had detectable pl6 
sequence in their plasma, while for HCC patients without cirrhosis, 22 of the 33 
patients had detectable pl6 sequences in their plasma. The proportion of methylated 
pl6 in plasma of HCC patients with and without ultrasonographic evidence of 
cirrhosis was not statistically significantly different (Mann-Whitney test, P = 0.201). 
For HBV carriers with cirrhosis, 3 of the 31 patients had detectable pl6 sequences in 
their plasma whereas 2 of the 24 HBV carriers without cirrhosis had detectable pl6 
sequences in their plasma. The proportion of methylated pl6 in plasma of HBV 
patients with and without ultrasonographic evidence of cirrhosis was not statistically 
significantly different (Mann-Whitney test, P = 0.878). 
” 78 
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Figure 5.3.1. Plasma concentrations of methylated GSTPl (A), SOCSl (B), APC 
(C) and pi6 (D) sequences after enzyme digestion in the plasma of 56 HCC patients 
and 55 HBV carriers with and without cirrhosis 
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5.4. Changes in the concentration of the tumor suppressor genes one month 
after surgical resection of the cancer 
Postoperative blood samples from 34 HCC patients were collected at one month 
after surgical resection of the liver. The concentrations of methylated TSGs in 
postoperative samples were compared to those of the preoperative samples. A 
general decrease in the concentration was observed for the four TSGs. The numbers 
of patients with detectable GSTPl, SOCSl, APC and pl6 sequences at diagnosis 
were 16，15, 14 and 22’ respectively, and 93.8%, 80%, 92.9% and 86.4% of these 
patients showed reduced concentrations at one month after surgery. The patients 
with undetectable TSGs sequences at diagnosis also showed undetectable levels at 
one month after surgery. The median concentration of methylated GSTPl sequences 
decreased from 5.95 x 10^ copies/L to 0 copy/L (Wilcoxon test, P<0.001). The 
median concentration of methylated SOCSl sequences decreased from 2.50 x 10^ 
copies/L to 0 copy/L (Wilcoxon test, P = 0.018). The median concentration of 
methylated APC sequences decreased from 6.87 x lO* copies/L to 1.01 x lO"^  
copies/L (Wilcoxon test, P = 0.007) . The median concentration of methylated pl6 
sequences decreased from 3.22 x 10^ copies/L to 2.36 x lO* copies/L (Wilcoxon test, 
P = 0.006). 
One sample showed an increase in concentration of pl6 from 1.20 x icT copies/L to 
3.07 X 10^ copies/L (2.5 fold) at one month after liver resection. Although this trend 
could not be observed in other TSG sequences, this sample showed high levels in 
both of the preoperative and the postoperative plasma of GSTPl and APC {GSTPl 
7.51 X lo6 copies/L and 2.30 x 10^ copies/L, respectively, and APC with 8.44 x 10^ 
copies/L to 2.26 x 10^ copies/L). No SOCSl sequences were present in the 
_ _ _ _ _ — 
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Figure 5.4.1. Reduction in the plasma levels of methylated GSTPl (A), SOCSl (B), 
APC (C) and pl6 (D) sequences at one month after tumor resection for the 34 HCC 
patients 
(y-axis indicates the concentrations of methylated TSGs sequences in copies/L) 
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5.5. Concurrent use of serum AFP level and plasma methylated markers for 
HCC diagnosis 
Serum AFP level is clinically used to detect HCC and the commonly applied cut-off 
value is 20 |j,g/L. However, the sensitivity of AFP measurement for HCC is only 
around 60% (detailed discussion in Chapter 1). In this part, I would like to 
demonstrate the improvement of detection rate by the combination of AFP and 
methylated markers. 
There were no correlation between the presence of at least one methylated markers 
and the serum AFP level > 20 jig/L for either HCC patients (Chi-square test:, P = 
0.857) or HBV carriers (Chi-square test, P = 0.525). 
Using a cut-off value of 20 |ig/L, 31 (55%) of the 56 HCC patients had an elevated 
AFP concentration and only 5 (9%) of the 55 HBV carriers had an elevated level. 
For the 45% of HCC patients with serum AFP concentration < 20 |ig/L, 18 patients 
(72%) of them had at least one methylated marker in plasma. After combining the 
serum AFP level and the presence of methylated TSGs markers, the diagnostic 
sensitivity was increased to 87.5% (49 of 56) with a slight decrease of specificity to 
78.2% (43 of55). 
The positive predictive value is the proportion of patients with positive test results 
who are correctly diagnosed. The negative predictive value is the proportion of 
patients with negative test results who are correctly diagnosed. Using the 
combination of AFP analyses and methylation marker, the positive predictive value 
^ 84 
Clinical application of methylated markers in the detection of HCC 
of the test is 96.2% and the negative predictive value is 86%. 
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Figure 5.5.1. Classification of 56 patients and 55 HBV carriers according to their 
serum AFP concentrations and the presence of methylated TSG markers in their 
plasma 
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5.6. Prognostic value of plasma methylated TSGs 
Kaplan-Meier survival curve is used to illustrate the survival probabilities of patients 
with detectable methylated GSTPl, SOCSl, APC and pl6 in plasma. Patients with 
and without detectable methylated GSTPl, SOCSl, APC and pl6 in plasma did not 
show significantly difference in disease-free survival probabilities (log-rank test, P = 
0.43，0.42, 0.73 and 0.15, respectively) (Figure 5.5.1). On the other hand, patients 
with two or more methylated markers in plasma at diagnosis had significantly poorer 
survival probability (log-rank test, P = 0.013) (Figure 5.5.2). 
Cox proportional hazards regression analysis was performed to determine if the 
prognostic value of the number of markers is independent of other parameters (Table 
5.5.1 and 5.5.2). The presence of two or more methylated markers in plasma at 
diagnosis was an independent predictor for disease free survival (Multivariate Cox 
proportional hazards regression, P = 0.039). 
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Figure 5.6.1. Recurrence-free survival curves for HCC patients. Patients with and 
without methylated (I) GSTPl, (II) SOCSl, (III) APC, (IV) pl6 in plasma at 
diagnosis 
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Figure 5.6.2. Recurrence-free survival curves for HCC patients 
The Kaplan-Meier survival curve of patients with 2 or more methylated markers in 
plasma showed significantly poorer disease-free survival than those with 0 or 1 
marker only at diagnosis. 
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Table 5.6.1. Univariate Cox-regression analysis of various factors on the 
recurrence-free survival in HCC patients 
95% confidence 
Covariate P value Hazard Ratio interval of 
hazard ratio 
No. of markers: >2 ^ 1.21-10.71 
Serum AFP: >20 |ag/L 0.107 ^ 0.85-5.71 
Cirrhosis 0.100 ^ 0.16-1.17 
No. of lesions: >1 0.976 0.34-3.03 
Size of tumor (in cm) 0.464 0.93-1.17 
Detectable GSTPl level 0.59-3.41 
Detectable SOCSl level 0.59-3.42 
Detectable ^ P C level 0.738 1.17 0.47-2.92 
Detectablepl6 level 0.166 2.04 0.75-5.60 
Table 5.6.2. Multivariate Cox-regression analysis of various factors on the 
recurrence-free survival in HCC patients 
95% confidence 
Covariate P value Hazard Ratio interval of 
hazard ratio 
No. of markers: >2 0.039 ^ 1.07-10.12 
Serum AFP: >20 |ag/L 0.100 2.29 0.86-6.14 
Cirrhosis 0.060 0.37 0.13-1.04 
No.of lesions: >1 0.685 1.26 0.42-3.81 
Size of tumor (in cm) 0.949 1.00 0.88-1.15 
SECTION IV: DISCUSSION 
~ - — 
Discussion 
Chapter 6: Discussion 
HCC is a tumor of global public health problem. The surveillance of HCC still relies 
on the measurement of serum AFP level which has been used for 40 years. The 
discovery of hypermethylation of the promoters of tumor suppressor genes in HCC 
tissues has opened up the possibility of using methylated TSGs as potential markers 
for HCC. Technically, MSP has been a commonly used technique for the detection 
of aberrantly methylated TSGs in multiple biological specimens, including blood 
samples. However, the detection rates of methylated sequences in blood have been 
shown by previous work to be much lower than the detection rates in tumor tissues. 
It was likely the result of low concentrations of tumoral DNA in plasma/serum 
(Chan & Lo，2007; Wong et al, 2003) and the degradation of DNA during the 
bisulfite conversion step of MSP (Grunau et al, 2001). In this regard, Chan et al. 
have developed a non-bisulfite-based approach to detect methylated RASSFIA in 
plasma. This method is based on the specific degradation of unmethylated sequence 
by methylation-sensitive restriction enzymes and the detection of undigestible 
methylated sequences by real-time PCR. They showed that this method is highly 
sensitive for detecting placental-derived methylated RASSFIA in maternal plasma 
(Chan et al’ 2006a) and methylated tumoral RASSFIA sequences in the serum of 
HCC patients (Chan et al, 2008a). Using this method, hypermethylated RASSFIA 
sequences could be detected in the serum of 93% HCC patients. As the sensitivity 
was remarkably enhanced by this non-bisulfite approach, low concentrations of 
methylated RASSFIA sequences were also detected in the serum samples of 58% 
HBV carriers. This observation was postulated to be due to the release of methylated 
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sequences from the nonmalignant hepatitic liver as the hypermethylation of 
RASSFIA was an early event in HCC pathogenesis and could be observed in patients 
with nonmalignant conditions such as cirrhosis and chronic hepatitis (Chan et al, 
2008a). In this project, I have studied the detectibility of other aberrantly methylated 
TSG in the plasma of HCC patients to determine if the combination of these markers 
can provide a more accurate diagnostic profile for HCC than using RASSFIA alone. 
6.1. Tumor and plasma detection of hypermethylated tumor suppressor genes 
The frequencies of hypermethylated GSTPl, SOCSl, APC and pl6 detected in 
tumor tissues using MSRE-qPCR were similar to previous studies using MSP which 
have been mentioned in Chapter 2.5.2. On the other hand, the detection rates of the 
tumor suppressor gene sequences in plasma were improved because the background 
unmethylated sequences were specifically degraded by the methylation-sensitive 
restriction enzymes. In contrast to the previous study on RASSFIA, the detection 
rates of hypermethylated GSTPl, SOCSl, APC and pl6 sequences in the plasma of 
HBV carriers were much lower. Hepatocarcinogenesis is a multistep process and 
promoter hypermethylation of RASSFIA involves in initial stage of HCC 
pathogenesis (Lee et al, 2003). Promoter hypermethylation of GSTPl, SOCSl, APC 
and pl6 genes may be a later event than that of RASSFIA and more specific to 
indicate the presence of a tumor. 
The significant correlation between the plasma concentration o f p l 6 sequences with 
tumor size may reflect the tumor load that has also been suggested by other study 
(Chan et al, 2008a; Chan et al, 2005a). And the lack of correlation between other 
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tumor suppressor genes and tumor size may be related to the relatively lower 
proportion of the sequences in plasma with a high background of methylated 
sequences derived from nonmalignant hepatitis liver tissues. 
In the current study, hypermethylation of GSTPl was detected in the tumor tissues 
of 78.6% HCC patients. Among the patients with GSTPl hypermethylated in tumor, 
methylated GSTPl sequences were detected in the plasma of 54.5% of them. This is 
translated to an overall detection rate of 42.9%. In contrast, only 3.6% HBV carriers 
and none of the healthy individuals had detectable methylated GSTPl sequences in 
plasma. 
Hypermethylated SOCSl sequences' were observed in 64.3% tumor tissues of HCC 
patients. Among these patients, methylated SOCSl sequences were detected in the 
plasma of 55.6% of them. This translates to an overall detection rate of 35.7% in 
HCC patients. In contrast, methylated SOCSl sequences were detected in the plasma 
of 3.6% in HBV carriers and 0% in healthy individuals. 
Hypermethylated APC sequences were observed in 87.5% tumor tissues of HCC 
patients. Among these patients, methylated APC sequences were detected in the 
plasma of 36.7% of them. This translates to an overall detection rate of 32.1% in 
HCC patients. In contrast, methylated APC sequences were detected in the plasma of 
0% in HBV carriers and 3.4% in healthy individuals. 
Hypermethylated pl6 sequences were observed in 89.3% tumor tissues of HCC 
patients. Among these patients, methylated pl6 sequences were detected in the 
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plasma of 66% of them. This translates to an overall detection rate of 58.9% in HCC 
patients. In contrast, methylated pl6 sequences were detected in the plasma of 9.1% 
in HBV carriers and none of the healthy individuals. 
Seventy-five percent of HCC tumor samples had the promoter of 3 or more 
methylated TSGs being hypermethylated while only one sample did not have any 
hypermethylation of any of the four TSGs. These results indicated that 
hypermethylation of TSGs is a prevalent event in HCC tissues and multiple signal 
transduction pathways are involved in the carcinogenesis of HCC. The detection 
rates of methylated sequence of these four TSGs range from 32.1 to 58.9%. In 
76.8% of HCC patients, one or more methylated TSGs were detected in the plasma. 
In contrast, only 14.5% of the HBV carriers and 3.4 % of the healthy individuals had 
one or more methylated TSGs detectable in plasma. Therefore, the detection of 
methylated TSGs in plasma appears to be a useful diagnostic marker for HCC. 
6.2. No effect of cirrhosis on plasma methylated DNA level 
Hepatitis virus B/C infection and cirrhosis are the major etiological factors for HCC. 
Previous studies have demonstrated the hypermethylation of TSGs in the hepatic and 
cirrhotic livers (Kaneto et al, 2001; Kondo et al, 2000; Roncalli et al, 2002). 
However, in this project, I have shown that methylated TSG sequences are 
infrequently detected in the plasma of subjects with chronic HBV infection. 
Furthermore, the difference in the plasma levels of TSGs between HCC patients and 
HBV carriers is independent of the cirrhotic status of the subjects. 
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6.3. Clearance of methylated TSG sequences after tumor resection 
To demonstrate the tumoral origin of the methylated TSG sequences in plasma, I 
have studied the changes in their concentrations after tumor resection. Above 80% 
of cases showed a reduction in the plasma concentration of methylated TSG 
sequences after surgical resection. 
One particular case showed a sharp increase of 2.5 fold methylated pl6 sequences 
7 7 
(from 1.2 X 10 copies/L to 3.1 x 10 copies/L) in plasma one month after surgery 
while the concentrations of the methylated GSTPl and APC sequences reduced from 
7.5 X 106 copies/L to 2.3 x 10^ copies/L and 8.4 x 10^ copies/L to 2.3 x 10^ copies/L 
respectively. No methylated SOCSl sequences were found in the preoperative and 
postoperative samples.This patient "was HBV-associated, had cirrhosis, had a single 
6 cm tumor and had an AFP value up to 20,000 |ig/L. HCC recurred two months 
after surgery and the patient passed away six months after surgery. 
For the observations concerning this sample, I postulated that in this patient the 
hypermethylation of the pl6 promoter would be the tumor specific change whereas 
the hypermethylation of the GSTPl and APC promoters might also be present in the 
background hepatitic and cirrhotic liver. The rapid rise in pl6 concentrations is in 
line with the rapid recurrence of the cancer and may indicate the increase in tumor 
load. On the other hand, the modest reduction in GSTPl and APC concentrations 
may represent the reduction of the liver size after hepatectomy. 
6.4. Concurrent use of serum AFP level and the presence of methylated 
markers in the plasma in HCC diagnosis 
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I have shown in the previous chapter that the detection rate for HCC was 77% using 
the combination of the four TSGs with a specificity of 86%. On the other hand, AFP 
measurement gave a sensitivity of 55% and a specificity of 91%. The sensitivity of 
detecting HCC increased to 88% when they are used together and the specificity is 
78%. Therefore, the combination of these two types of markers might improve the 
diagnostic accuracy of the existing surveillance program and improve the overall 
survival of HCC patients. 
6.5. Prognostic significance of circulating methylated tumor markers 
In addition to being useful for detecting HCC, these methylated markers are also of 
prognostic potential. It is interesting that the survival was not significantly correlated 
with the presence of any individual methylated TSGs at diagnosis. This finding is 
consistent with the observations in other previous studies on esophageal cancer 
(Brock et al, 2003; Hibi et al, 2001), lung cancer (Kim et al, 2005) and prostate 
cancer (Maruyama et al, 2002). In contrast, the presence of two or more methylated 
markers in plasma at diagnosis was associated with a poorer survival. There are 
several possible explanations for this observation. First, patients with more 
methylated markers in plasma may have a higher tumor load such that a higher and 
detectable concentrations of tumoral DNA are present in their plasma. Second, 
tumors may be more aggressive when more TSGs are methylated. Previous studies 
suggested that DNA methylation may accumulate as the molecular clock of a cancer 
advances with time (Brock et al, 2003). 
The prognostic value of the number of TSG present in plasma was further shown to 
be not confounded by parameters including serum AFP level, cirrhosis, the size of 
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the tumor and the number of lesions in the liver (Multivariate Cox-regression 
analysis, P=0.04, HR=3.4). 
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Chapter 7: Conclusions and future perspectives 
Over the last decade, significant progress has been made to understand the 
molecular mechanisms involved in carcinogenesis. In this regard, hypermethylation 
of TSGs has been shown to be an important step in cancer formation, particularly in 
HCC where TSG mutations are uncommon. The advances in molecular biology have 
enabled the detection of such changes in blood or other body fluids and opens up 
new possibilities for non-invasive diagnosis of cancers. In this study, I have 
developed methylation-sensitive restriction enzymes-mediated quantitative PCR 
assays for the sensitive detection of aberrantly methylated TSGs including GSTPl, 
SOCSl, APC and pi6. The reduction of methylated sequences in plasma at one 
month after tumor resection is highly suggestive for the tumoral origin of the 
circulating methylated DNA. With multiple tumor suppressor genes {GSTPl, SOCSl, 
APC and pl6) combined in a panel, a detection rate of 76.8% can be achieved 
whereas only 14.5% in HBV carriers and 3.4% in healthy individuals had detectable 
TSGs in plasma. These methylated DNA markers can also be applied in conjunction 
with the existing HCC marker, AFP. This has improved the 55% sensitivity of AFP 
analysis to the 87.5% of using both markers. 
Further improvement of detection accuracies by digital PCR 
In this study, the experimental part was mostly dependent on the platform of 
real-time quantitative PCR which is inexpensive and can handle a moderate number 
of samples at a time. In fact, the detection sensitivity can still be improved if using 
another platform such as microfluidics digital PCR (Dube et al, 2008; Lun et al, 
2008) that can generate more precise results. Digital PCR has been shown to be 
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superior to standard real-time PCR for detecting low concentration of targets (Yung 
et al, 2009). Digital MethyLight has been successfully used to detect 
hypermethylated sequences in plasma from breast cancer patients in a triplex 
manner (Weisenberger et al, 2008). 
Routine clinical utility of methylated DNA markers 
The measurement of serum AFP level is the most common blood test for HCC. 
However, it offers a sensitivity of only 40-60% and a specificity of 80-90% (Farinati 
et al, 2006; Wright et al, 2007). With the combination of multiple methylated DNA 
markers and serum AFP, a detection rate of 87.5% can be achieved with a slight 
decrease of specificity to 78.2% in HBV carriers. On the other hand, MSRE-qPCR is 
relatively inexpensive and technically simple. Therefore, the methylated DNA 
markers may be suitable for routine clinical practice for HCC diagnosis. 
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Diagnostic potential of methylated DNA markers for other cancers 
Promoter hypermethylation of GSTPl, SOCSl, APC or pl6 are observed in many 
cancers. For example, methylated GSTPl sequences were detected in prostate cancer 
patients (Goessl et al, 2000) and methylated APC sequences were detected in 
oesophageal cancer patients (Kawakami et al’ 2000). MSRE-qPCR assays 
developed in this study can be transferred to detect other cancers with 
hypermethylation of the GSTPl, SOCSl, APC or pl6 genes. MSRE-qPCR assays 
for other tumor suppressor genes can also be designed according to the methylation 
profiles of certain types of cancers. 
Diagnostic potential of methylated DNA markers in other biological samples 
MSRE-qPCR is sensitive in detecting methylated tumor suppressor genes sequences 
in plasma. The application of MSRE-qPCR may further be expanded to other body 
fluids such as urine and sputum samples. For instance, multiple methylated 
sequences have been detected in 90.9% urine sediment in bladder cancer using MSP 
(Chan et al’ 2002). Therefore, with more sensitive MSRE-qPCR, the detection rate 
may be further improved. 
The possibility of predicting the occurrence of HCC in healthy subjects or hepatitis 
carrier 
Besides diagnostic utility, the methylated DNA markers may potentially be 
developed into predictive markers to predict the risk of an individual to develop 
HCC after certain period of time. Hypermethylation in promoter of tumor suppressor 
genes is an early event in carcinogenesis. It can be the first hit in Knudson's two-hit 
hypothesis. In many studies, methylated tumor suppressor genes sequences are also 
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detectable in premalignant tissue. Studies of the correlation between methylation 
statuses in premalignant tissues and the risk of developing HCC in the future are 
worthwhile. In this study, the methylation-sensitive restriction enzymes do not cut 
the DNA if the cytosines on both strands at the recognition sites are methylated, 
such that, the digestion is blocked by the methylated cytosines. Some 
methylation-sensitive restriction enzymes do not cut DNA with only one methylated 
cytosine at recognition sites. Assays can be further developed to detect the partially 
methylated statuses in DNA. 
Further investigations on the diagnostic and prognostic potential of this panel of 
tumor markers are warranted as well as the clinical utility of the markers to predict 
chemotherapeutic response. The ‘ evaluation of the assays in high-throughput 
platform and large-scale studies are needed to further validate the results. In the near 
future, methylation markers have a great potential to develop into markers using in 
routine clinical diagnostics. 
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